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Summary 
I 
Summary  
α-Synuclein is a soluble, cellular protein that in a number of neurodegenerative diseases, 
including Parkinson's disease, multiple system atrophy, and Lewy body dementia 
aggregates into pathological protein deposits. Principles how misfolded and aggregated 
α-synuclein is transmitted within the central nervous system (CNS) causing neurologic 
disease were found to be similar to those of prions. Misfolded α-synuclein can be 
transmitted between cells and act as a seed, recruiting native, unfolded α-synuclein to 
form insoluble aggregates. The mechanisms and the routes through which pathogenic 
proteins enter the CNS causing progressive disease are still not completely understood. 
The work in this thesis confirms previous findings indicating that α-synuclein fibrils 
intracerebrally injected into wild-type mice for α-synuclein can induce neuropathology in 
interconnected brain regions as similarly observed in sporadic Parkinson's disease. In 
contrast, α-synuclein fibrils injected into the tongue muscle of wild-type mice for α-
synuclein did not neuroinvade the CNS causing α-synuclein pathology. Moreover, the 
present study is the first to show, that α-synuclein fibrils peripherally injected into the 
tongue and the peritoneum of mice overexpressing human α-synuclein, can neuroinvade 
the CNS, cause widespread α-synuclein pathology and induce neurologic symptoms. The 
induction of neuropathology was accompanied by neuroinflammation as monitored by 
astrocytic gliosis and microgliosis. In addition, the study presented here indicates that  
exposure of mice overexpressing human α-synuclein with pathogenic α-synuclein 
aerosols was not sufficient for α-synuclein prionoids to enter the brain via the olfactory 
epithelium and induce neuropathology. In summary, these findings corroborate the 
prionoid character of misfolded α-synuclein using similar routes like prions to 
neuroinvade brain and spinal cord and induce neurologic disease. 
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II 
Zusammenfassung 
α-Synuclein ist ein lösliches, zelluläres Protein, das in seiner fehlgefalteten Form zu 
pathologischen Proteinablagerungen aggregiert. Diese Ablagerungen sind 
charakteristisch für eine Vielzahl von neurodegenerativen Erkrankungen wie Morbus 
Parkinson, Multisystematrophie und Lewy-Body-Demenz. Es hat sich gezeigt, dass die 
Mechanismen nach denen sich fehlgefaltetes und aggregiertes α-Synuclein Protein 
innerhalb des Zentralnervensystems (ZNS) ausbreitet und neurologische Erkrankungen 
auslöst denen von Prionen sehr ähnlich sind. Fehlgefaltetes α-Synuclein kann zwischen 
Zellen übertragen werden und nicht gefaltetes, natives α-Synuclein dazu veranlassen 
unlösliche Aggregate zu bilden. Die Mechanismen und die Wege, durch die pathogene 
Proteine in das ZNS einwandern und folglich progressive neuronale Erkrankungen 
auslösen, sind noch nicht vollständig bekannt. Die Ergebnisse dieser Thesis bestätigen 
vorhergehende Beobachtungen, dass pathogene α-Synuclein Fibrillen, die intrazerebral 
in Wildtyp-Mäuse injiziert wurden, Neuropathologie in miteinander verbundenen 
Gehirnregionen hervorrufen, wie es in ähnlicher Weise in Patienten mit sporadischem 
Morbus Parkinson beobachtet wurde. Die Injektion von fehlgefaltetem α-Synuclein in 
den Zungenmuskel derselben Mauslinie führte jedoch nicht zur Einwanderung von 
pathogenem α-Synuclein in das ZNS. Zudem zeigt die vorliegende Arbeit erstmalig, dass 
α-Synuclein Fibrillen, die peripher in den Zungenmuskel oder in das Peritoneum von 
Mäusen, die humanes α-Synuclein überexprimieren, injiziert wurden in das ZNS 
einwandern und neben einer ausgeprägten Neuropathology auch neurologische 
Symptome auslösen. Mit dem Fortschreiten der Neuropathologie ging auch eine 
neuronale Entzündung einher, die anhand von astrozytischer Gliose und Mikrogliose 
nachgewiesen werden konnte. Darüber hinaus zeigt diese Studie, dass pathogene α-
Synuclein Aerosole mit denen α-Synuclein überexprimierende Mäuse inhaliert wurden, 
das olfaktorische Epithel nicht passieren und Neuropathologie auslösen konnten. Diese 
Erkenntnisse bestätigen, dass fehlgefaltetes α-Synuclein ähnliche Übertragungswege und 
Mechanismen wie Prionen nutzt, um in Gehirn und Rückenmark einzuwandern und dort 
eine neurologische Erkrankung auszulösen. 
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Introduction 
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1 Introduction 
1.1 The prion protein and prion-like behavior 
In several neurodegenerative diseases the assembly of misfolded proteins into highly 
ordered so-called amyloids is a prevalent principle (Table 1.1). The common structural 
motif that characterizes amyloids is the cross-β-sheet conformation. Filamentous 
amyloids are, despite their generic cross-β-sheet conformation, highly polymorphic 
(Selkoe, 2003). One of the best-characterized amyloids is the prion protein. In prion 
diseases, the cellular prion protein PrPC undergoes a conformational change into a 
protease-resistant, β-sheet-rich prion conformation PrPSc. This infectious prion 
conformation can act as a seed and promote the conversion of PrPC into its amyloid 
conformation PrPSc. This process initiates prion replication, polymerization, and 
propagation, which is a self-sustained seeding mechanism (Cohen et al., 1994). Notably, 
not only the stable PrPSc bears infectivity, also its small protease-sensitive intermediates 
show similar to higher infection potential (Aguzzi and Lakkaraju, 2016). 
 
Table 1.1 Brain diseases that are characterized by progressive misfolding and aggregation of proteins  
 
 
Iatrogenic transmission of prions causing Creutzfeldt-Jakob disease (CJD) was reported 
when children with stunted growth were treated with cadaveric growth hormone. 
Similarly, bovine spongiform encephalopathy (BSE) in cattle was transmitted to humans 
Disease Protein Pathology Strains Transmissible Bona fide 
infectivity 
Prion 
diseases 
PrPSc 
extracellular plaques, 
oligomers are outside 
neurons 
yes yes yes 
Parkinson’s 
disease 
 
α-synuclein neuronal cytoplasma 
 
maybe 
 
yes 
 
not shown 
Alzheimer’s 
disease 
amyloid-β 
extracellular plaques, 
tangles in neuronal 
cytoplasm 
yes yes not shown 
Tauopathies tau 
tangles in neuronal 
cytoplasm 
yes yes not shown 
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as a variant of CJD (vCJD) after consumption of prion-infected meat and was further 
transmitted among humans via blood transfusions (Brown et al., 2012; Hewitt et al., 2006; 
Hill et al., 1997). It is also known that prions are transmissible among sheep causing 
scrapie or among deer and elk causing chronic wasting disease (CWD) (Tamgüney et al., 
2009b; Tamgüney et al., 2012). Although prion diseases remain the only protein-
misfolding diseases that are transmissible between individuals, there is growing evidence 
that there are numerous parallels between the prion protein and other proteins associated 
with neurodegenerative diseases. These proteins include for example: α-synuclein as the 
relevant agent of Parkinson’s disease, amyloid-β associated with Alzheimer’s disease 
(AD), and the microtubule associated protein tau (MAPT) that is linked with AD and 
other tauopathies. These amyloidogenic proteins do not seem to be naturally transmitted 
between individual hosts like common –so called– bona fide prions, but resemble prions 
in many other ways. The term “prion-like” or “prionoid” was suggested to describe some 
aspects of their biological properties (Table 1.1) (Aguzzi, 2009; Aguzzi and Lakkaraju, 
2016; Aguzzi and Rajendran, 2009). The only reference for iatrogenic transmission of 
amyloidogenic proteins has been suggested for amyloid-β. In this report, the occurrence 
of amyloid-β pathology and cerebral amyloid angiopathy has been confirmed in CJD 
patients that were previously treated with infected growth hormone (Jaunmuktane et al., 
2015b).  
 
Prions in distinct conformations have divers biochemical and functional properties that 
cause individual pathologies and clinical manifestation. According to their biochemical 
and pathophysiological properties, they have been classified into strains (Collinge and 
Clarke, 2007; Tanaka et al., 2004). Analog to prions, amyloid-β and tau also occur as 
individual strains that can be transmitted to hosts and cause distinct disease phenotypes 
(Sanders et al., 2014; Stohr et al., 2014; Watts et al., 2014). Similarly, conformational 
strains have also been described for disease-associated α-synuclein and hypothesized to 
cause the heterogeneity of synucleinopathies. (Bousset et al., 2013; Guo et al., 2013; 
Peelaerts et al., 2015). There is evidence that the bacterial endotoxin lipopolysaccharide 
(LPS) affects the biochemical and pathogenic properties of recombinant α-synuclein 
causing distinct pathological phenotypes (Kim et al., 2016). Despite that α-synuclein has 
some concordant characteristics with the prion protein, there is no current evidence for 
its iatrogenic transmissibility. 
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1.1.1. Intercellular transmission of prions 
Oral ingestion of prion-infected material seems to be the most relevant route for prions to 
naturally enter the central nervous system (CNS) under non-experimental conditions 
(McBride et al., 2001). The alimentary route is interconnected to the enteric nervous 
system (ENS) that autonomously controls the functionality of the gastrointestinal tract. 
In rodents it has been shown that after entering the ENS, prions primarily use efferent 
fibers of the vagus nerve and the splanchnic nerves to neuroinvade brain and spinal cord 
(Beekes et al., 1998; McBride et al., 2001). Furthermore, prions peripherally injected into 
muscles like the femoral biceps (hindlimb) or the lingual muscle (tongue) are also able to 
rapidly infect the CNS (Bartz et al., 2003; Bosque et al., 2002). Similarly, intraperitoneal, 
intraocular, and intravenous injections have been described as additional peripheral 
entrance points for prions to neuroinvade the CNS (Bartz et al., 2002; Kimberlin and 
Walker, 1980, 1986). Among these non-neuronal routes, infection into the tongue muscle 
was shown to be the most efficient transmission route for prions. Prions injected into the 
tongue can rapidly neuroinvade the brain stem causing disease after an incubation time 
of two weeks or be reversely transmitted from the brain to the tongue (Bartz et al., 2003; 
Mulcahy et al., 2004). Although these peripheral routes are less relevant for naturally 
transmitted agents, these findings implicate that the peripheral nervous system including 
the ENS is likely involved in the spread of prion infectivity. 
 
1.2 Synucleinopathies  
Neurodegenerative diseases such as Parkinson’s disease (PD), multiple system atrophie 
(MSA) and Lewy body dementia (LBD) that are pathologically characterized by the 
accumulation of misfolded α-synuclein proteins within the nervous system are referred to 
as synucleinopathies. PD as the second most common neurodegenerative disease besides 
Alzheimer’s disease is associated with a set of clinical motor symptoms like bradykinesia, 
resting tremor, rigidity, postural instability and periods of freezing, and non-motor 
symptoms like olfactory deficits, sleep disorders, and cognitive impairments (Gallagher 
et al., 2010; Klingelhoefer and Reichmann, 2015). Besides idiopathic PD, which 
constitutes the prevalent form of PD, familial cases have been described (Pankratz and 
Foroud, 2004).  
 
The accumulation of misfolded α-synuclein in the CNS of PD patients proceeds gradually 
and follows a predetermined topographical pattern. According to the stereotypic 
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progression over time the PD-related α-synuclein pathology has been classified in six 
developmental stages (Braak et al., 2003a). It has been shown that the course of PD can 
take years or decades until the disease reaches advanced stages (3rd to 6th) with clinical 
manifestation. During the proceeded disease stages, accumulation of α-synuclein 
aggregates induces the loss of dopaminergic neurons in the substantia nigra pars compacta 
projecting to the striatum. This neuronal loss is cause for the characteristic motor 
symptoms (Hirsch et al., 1988; Masliah et al., 2000). In many PD cases the pathological 
features and the loss of dopaminergic neurons are not only restricted to the substantia 
nigra but have also been found in other parts of the nervous system such as the basal 
forebrain (nucleus basalis of Meynert) and the brainstem (motor nucleus of the vagus and 
locus coeruleus) (Spillantini and Goedert, 2000).  
 
1.2.1 Biology of α-synuclein 
α-Synuclein is a small acidic 140 amino acid protein that in its native, soluble form is 
abundant at the presynaptic terminals of neurons. α-Synuclein associates with membranes 
and binds to synaptic vesicles to maintain their synaptic vesicle pools suggesting its role 
in neurotransmitter release (Fortin et al., 2004; Jo et al., 2000). Although the majority of 
native α-synuclein is found within the nervous tissue, the red blood cells have been shown 
to contain relatively large concentrations of α-synuclein, too (Barbour et al., 2008; Bendor 
et al., 2013).  
 
The human SNCA gene encoding α-synuclein is located on chromosome 4q21.3-q22 and 
comprises 111 kb (Fig.1.1). The gene spans a set of seven exons and five of those, exon 
2 to exon 6, correspond to its coding region. The amino acid sequence is divided into 
three parts: an amphipathic region, a non-amyloid β component (NAC) domain and an 
acidic tail. A cluster of KTKEGV consensus repeats characterizes the N-terminal 
sequence. A 12-amino acid stretch within the hydrophobic NAC region is a prerequisite 
for its polymerization into fibrils (Giasson et al., 2001). The entire sequence of α-
synuclein is highly conserved between mouse and human and differs only in seven amino 
acids (Appendix Fig. 5.1) (Maroteaux et al., 1988; Murphy et al., 2000). Gene 
duplications and triplications as well as six missense mutations A30T, E46K, H50Q, 
G51D, A53E, and A53T within the human SNCA sequence cause an autosomal-dominant 
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form of familial PD with an early disease onset (Kruger et al., 1998; Lesage et al., 2013; 
Polymeropoulos et al., 1997; Singleton et al., 2003; Zarranz et al., 2004).  
 
 
 
Fig. 1.1 Schematic view of human α-synuclein. Chromosomal localization of the α-synuclein gene (top 
panel). Coding region of α-synuclein represented by its m-RNA (middle panel). The amino acid sequence 
of α-synuclein is divided into an amphipathic region, a non-amyloid β component (NAC) domain and an 
acidic tail. Six missense mutations associated with familial PD and the phosphorylation sites at serine 129 
and tyrosine 125 are indicated (bottom panel) (adapted from Venda et al., 2010, with permission from 
Elsevier). 
 
 
1.2.2 Aggregation and toxicity of α-synuclein  
Under physiological conditions, the α-synuclein protein occurs mostly as unfolded 
monomer. When it becomes pathological, it forms insoluble, highly ordered 
conformations with toxic properties. Notably, the native α-synuclein does not only occur 
as monomer but also as helically folded tetramer that prevents its pathological 
aggregation (Bartels et al., 2011; Wang et al., 2011). Polymerization of the monomeric 
α-synuclein into disease-associated fibrillar structures is a multi-step process beginning 
with the conversion of monomers into dimers that consequently polymerize into various 
intermediate oligomeric structures e.g. ring-like oligomers (Fig.1.2). Such intermediate 
forms of α-synuclein are generally termed protofibrils. Misfolded α-synuclein recruits 
unfolded monomers through conformational templating and induces them to adopt a β-
rich conformation. This amyloid conformation can polymerize and in turn seed its 
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conformation to unfolded proteins by a self-perpetuating seeding mechanism. Finally the 
oligomers assemble to β-sheet-rich amyloid fibrils forming deposits in the neuronal 
cytosol called Lewy bodies (LBs). This Polymerization and assembly occurs either within 
the cytoplasm or is associated with membranes. (Kalia et al., 2013; Lashuel et al., 2013).  
 
 
Fig. 1.2 Mechanism of α-synuclein polymerization. Unfolded, monomeric α-synuclein polymerizes 
stepwise into β-sheet-enriched amyloid fibrils that finally assemble to Lewy bodies (adapted from Lashuel 
et al., 2013, with permission from Nature Publishing Group). 
 
 
Various studies support the idea that not only amyloid fibrils bear toxic properties. The 
intermediate protofibrils and oligomers show a similar or even enhanced cellular 
virulence. Mutated α-synuclein molecules are less prone to fibrillize when analyzed in-
vitro. Consequently, the reduced amount of fibrils leads to higher concentrations of 
oligomeric intermediates, which probably cause the increased toxicity in in-vivo models 
(Conway et al., 2000; Kalia et al., 2013; Karpinar et al., 2009; Winner et al., 2011). 
 
1.2.2.1  Posttranslational modifications  
Phosphorylation at serine 129 (Fig. 1.1) has been described as the dominant 
posttranslational modification of α-synuclein found in synucleinopathy lesions (Anderson 
et al., 2006; Fujiwara et al., 2002). Therefore it has been assumed, that phosphorylation 
plays a predominant role during disease progression. Moreover, in-vitro experiments 
indicate that monomeric α-synuclein phosphorylated at serine 129 is more prone to 
aggregate and polymerize into fibrils. On the contrary, the phosphorylation at tyrosine 
125 (Fig. 1.1) diminishes the propensity of α-synuclein to form amyloids (Fig. 1.2) 
(Venda et al., 2010). 
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Oxidative stress can cause as well posttranslational modification of α-synuclein. The 
abundance of reactive oxygen and nitrogen species generates nitrating factors that can 
alter the protein structure of α-synuclein and influence its pathogenic properties. 
Particularly, nitrated tyrosine residues were abundantly found in deposits of misfolded α-
synuclein when analyzed by immunohistochemical methods (Duda et al., 2000; Giasson 
et al., 2000; Ischiropoulos and Beckman, 2003). 
 
Furthermore, deposits of misfolded α-synuclein are posttranslationally modified by the 
attachment of ubiquitin. Even the α-synuclein, phosphorylated at serine 129, is targeted 
for mono -and diubiquitination and might have implications for disease progression 
(Spillantini and Goedert, 2000; Tofaris et al., 2003). Not only ubiquitin itself, but also its 
cytoplasmic binding protein p62 that binds noncovalently to ubiquitin is frequently used 
as aggregation marker (Kuusisto et al., 2001). 
 
1.2.2.2  Unbalanced cellular homeostasis  
Both properly working quality-control and degradation systems are needed to maintain 
cellular homeostasis. Perturbations affecting protein synthesis, folding and degradation 
can result in uncontrolled protein aggregation with a subsequent fibril formation and a 
functional disruption of the cell. In a functioning cell, molecular chaperones control the 
conformation of proteins and refold misfolded proteins back to their native structure. 
Misfolded protein conformers can be directly eliminated via the ubiquitin-proteasomal 
system (UPS) and the autophagy-lysosomal pathway (ALP) (Kalia et al., 2013; Tyedmers 
et al., 2010). To target proteins for proteasomal degradation at least four ubiquitin 
conjugates are added to their lysine residues. Only thereafter the targeted protein can be 
transported to the proteasome. Importantly, only unfolded, soluble proteins can enter the 
proteasome (Bence et al., 2001; Rubinsztein, 2006). Since proteasome-associated 
degradation only works for unfolded proteins, the lysosomal pathway represents the 
default way to deconstruct aggregated proteins. The autophagy-lysosomal pathway can 
be separated in microautophagy, macroautophagy, and chaperone-mediated autophagy. 
For lysosomal degradation the proteins are trapped by the autophagosome, a vesicle with 
a double-membrane that fuses with the lysosome to form an autophagolysosome. The 
proteinaceous content of the autophagolysosome is finally fractionized by lysosomal 
hydrolases (Rubinsztein, 2006).  
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Both clearance mechanisms have been described to be relevant for the degradation of α-
synuclein, although aggregated α-synuclein seems to be less prone to degradation (Webb 
et al., 2003). In contrast to wild-type α-synuclein, the A53T and A30P mutants of α-
synuclein (Fig. 1.1) are not efficiently degraded via the lysosomal pathway. Moreover, 
the proteasomes found in cases of sporadic PD showed an altered structure with an 
impaired proteolytic activity (Cuervo et al., 2004; McNaught and Jenner, 2001). Proteins 
that are resistant to degradation, such as α-synuclein in human and animal 
synucleinopathies were found to colocalize with ubiquitin and its binding protein p62 
(sequestosome-1). Therefore both proteins are used as marker targeting pathological 
aggregated proteins (Ahmed et al., 2012; Komatsu et al., 2007; Kuusisto et al., 2001; 
Lowe et al., 1988). Impairment of the proteasomal and lysosomal machinery by binding 
of misfolded α-synuclein might additionally reduce the degradation of other proteins and 
further contribute to the accumulation of harmful aggregates in the cell.  
 
1.2.2.3  α-Synuclein pathology 
One pathological hallmark of surviving neurons in PD is the accumulation of misfolded 
α-synuclein in form of neuronal deposits in the cytosol termed Lewy bodies (LBs) or in 
neuronal processes termed Lewy neurites (LNs, Fig. 1.3) (Spillantini et al., 1997).  
 
Fig. 1.3 Immunostaining for α-synuclein in the brain of a DLB patient. a) Positive-staining for a Lewy 
neurite in the substantia nigra. b) Pigmented nerve cell of the substantia nigra shows positive-staining for a 
Lewy body (adapted from Spillantini et al., 1997, with permission from Nature Publishing Group). 
 
 
The cytoplasmic inclusions are composed of insoluble, filamentous and granular α-
synuclein with a cross-β sheet conformation characteristic for amyloids. In contrast to 
PD, MSA is characterized predominantly by the deposition of α-synuclein within glial 
cytoplasmic inclusions (GCI) restricted to oligodentrcytes (Serpell et al., 2000; Spillantini 
et al., 1998; Spillantini and Goedert, 2000; Spillantini et al., 1997). Besides α-synuclein 
as the major component of the LBs, further constituents are ubiquitin and neurofilaments, 
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which are stratified into concentric layers. Triple immunofluorolabeling has shown that 
ubiquitin builds the LB center surrounded by α-synuclein and neurofilament as the 
outermost layer (Kanazawa et al., 2008). 
 
1.3 Intercellular transmission of α-synuclein 
Extensive neuropathological examinations of human tissue identified that the progression 
of α-synuclein pathology follows a stereotypic pattern (Braak et al., 2003a). The 
pathology progression could be determined by the distribution of phosphorylated α-
synuclein aggregates over time (Lewy bodies/ Lewy neurites). In this respect the olfactory 
bulb in the brain and the enteric plexus of the gastrointestinal system were described as 
initial points from where the disease could start and propagate to distal parts in the 
cerebrum. The initiation of α-synuclein pathology either in the nasal tracts or the 
gastrointestinal system was proposed as the “dual hit hypothesis”. It suggests that 
neurotropic pathogens can be transported to the lower brainstem: a) anterogradely along 
olfactory tracts entering the nasal mucosa or b) retrogradely from the gastrointestinal tract 
by entering the vagus nerve (Hawkes et al., 2007, 2009). The distribution of α-synuclein 
aggregates along interconnected neuroanatomical regions indicated that only a certain 
type of neuron is vulnerable to pathological α-synuclein. These selective vulnerable 
neurons were identified as long, thin projection neurons that are mainly unmyelinated 
(Braak and Del Tredici, 2004).  
 
Transmission of misfolded α-synuclein between cells has been suggested after observing 
the results of neuronal grafting experiments in humans. Embryonic dopaminergic neurons 
that had been therapeutically grafted into the striata of PD patients had accumulated 
misfolded α-synuclein after fourteen years. This suggests that misfolded α-synuclein is 
transferred between cells and induces misfolding by a seeding mechanism (see Fig. 1.2) 
(Kordower et al., 2008; Li et al., 2008). Inoculation experiments utilizing both α-
synuclein overexpressing and wild-type mice indicated that intracerebral injection of 
pathogenic α-synuclein lead to spread of pathology from the injection site to synaptically 
interconnected brain regions (Bernis et al., 2015; Luk et al., 2012a; Luk et al., 2012b; Rey 
et al., 2013; Sacino et al., 2013b; Watts et al., 2013). However, several studies in α-
synuclein wild-type mice injected with recombinant α-synuclein fibrils do not show 
uniform results regarding the disease phenotype and spread of pathology within the CNS 
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(Luk et al., 2012a; Masuda-Suzukake et al., 2013; Sacino et al., 2013a). Despite the 
findings that α-synuclein fibrils can cause neuropathology like prions after CNS injection 
(Lasmezas et al., 1997) it is unclear whether injection via peripheral routes such as the 
tongue muscle, the peritoneum, or the nasal tracts can result in CNS disease. 
 
1.3.1 Mechanisms for cellular transfer of α-synuclein  
After misfolded α-synuclein is internalized into the cytoplasm of neurons, it is further 
transported along neuronal axons and propagated to neighboring neurons (Desplats et al., 
2009; Freundt et al., 2012; Volpicelli-Daley et al., 2011). Different mechanisms 
mediating the cellular transfer of misfolded proteins between neurons have been 
proposed. Misfolded and aggregated α-synuclein may be released from a donor cell into 
the extracellular continuum via a) diffusion or b) membrane-bound vesicles (Fig. 1.4) 
(Danzer et al., 2012; Emmanouilidou et al., 2011; Emmanouilidou et al., 2010; Guo and 
Lee, 2014; van Dijk et al., 2014). Proteins that are associated with neurodegenerative 
diseases like microtubule associated protein tau (MAPT), polyglutamine (PolyQ), 
superoxide dismutase 1 (SOD1), or prions are potentially internalized into recipient 
neurons through (1) direct diffusion, (2) endocytosis, (3) receptor-mediated endocytosis, 
(4) exosome-mediated endocytosis, and (5) nanotube tunneling (Fig. 1.4) (Frost et al., 
2009; Gousset et al., 2009; Munch et al., 2011; Ren et al., 2009; Wu et al., 2013). For α-
synuclein receptor-mediated endocytosis has been described as a primary pathway to 
enter recipient cells (Desplats et al., 2009; Guo and Lee, 2014; Hansen et al., 2011; 
Holmes et al., 2013; Mao et al., 2016). After internalization of misfolded α-synuclein into 
the cytoplasm of a recipient neuron, endogenous monomers are recruited for fibrillization.  
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Fig. 1.4 Potential mechanisms of α-synuclein propagation between neighboring neurons. After 
secretion of α-synuclein from the releasing neuron into the extracellular space, α-synuclein seeds can be 
internalized from the recipient neuron via five different mechanisms (adapted from Guo and Lee, 2014, 
with permission from Nature Publishing Group). 
 
 
1.4 Inflammation in neurodegenerative diseases  
Neurodegenerative diseases often have a neuroinflammatory component that is 
characterized by the activation of astrocytes and microglia (Amor et al., 2014; Wyss-
Coray and Mucke, 2002). Particularly, abundance of activated microglia and astrocytes 
has been demonstrated by histological analysis of the substantia nigra in PD patients 
(Damier et al., 1993; Imamura et al., 2003). 
 
1.4.1 Microglia 
Glial cells including oligodendrocytes, microglia and astrocytes are the non-neuronal 
cells of the CNS that help to maintain the homeostasis of the neuronal environment (Allen 
and Barres, 2009). Microglia are the resident macrophages and innate immune cells of 
the brain that constantly monitor the neuronal microenvironment to detect any injury or 
pathogenic incidence. In case of any tissue damage or infection, the microglia migrate to 
the place of injury and change their morphology. Activated microglia release pro-
inflammatory cytokines and chemokines that recruit additional immunregulatory cells for 
the adaptive immune response. The activation of the adaptive immunity is receptor-
mediated and controls diverse signaling transduction pathways. The latter regulate the 
expression of proteins covering a wide range of functions to stem the cause of disturbance 
(Glass et al., 2010; McGeer and McGeer, 2008; Rivest, 2009). The high turnover of 
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reactive oxygen species and proinflammatory cytokines like: tumor necrosis factor α 
(TNF-α), interleukin-1 β (IL-1 β) and interleukin-6 (IL-6) can cause toxicity and possibly 
neurodegeneration. There is growing evidence that the abundance of misfolded α-
synuclein is able to activate microglia resulting in microgliosis and consequently 
promotes neuronal damage and disease progression (Theodore et al., 2008; Zhang et al., 
2005). 
 
1.4.2 Astrocytes 
Astrocytes as cellular organizers control the neuronal metabolism, cell-to-cell 
communication, and are additionally involved in repair mechanisms. Similarly to 
microglia, activated astrocytes become hypertrophic, change their morphology and 
express a set of regulatory genes resulting in reactive astrocytic gliosis. After severe tissue 
damage, astrocytes proliferate and are involved in the formation of glial scars (Maragakis 
and Rothstein, 2006; Sofroniew, 2009). α-Synuclein released from neurons can be 
internalized by astrocytes and aggregate as glial inclusions that evoke a 
neuroinflammatory response (Lee et al., 2010). Astrocytes stand in close relationship to 
microglia, communicating via the exchange of pro- and anti-inflammatory signals. One 
important hallmark of reactive astrocytes is the robust upregulation of the glial fibrillary 
acidic protein (GFAP), which can be detected by immunohistochemical staining. 
Upregulation of GFAP, predominantly expressed in the CNS, has been demonstrated to 
indicate neuroinflammation and neuronal injury and increases with its severity. Based on 
these findings, a transgenic reporter mouse model was established. This model expresses 
the luciferase gene under control of the GFAP promoter to monitor neuroinflammation in 
a non-invasive way (Zhu et al., 2004).  
 
1.5 Animal models to study synucleinopathies  
1.5.1 Intoxication mouse models 
To study the etiology of human synucleinopathies in more detail, animal models that 
recapitulate the main pathophysiological features of the disease are indispensable. One of 
the first intoxication models used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
as treatment for animals to mimic several of the characteristic symptoms of PD. The 
intoxication changes the mitochondrial metabolism that lead to an increased turnover of 
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reactive oxygen species enhancing the propensity of α-synuclein to aggregate and form 
pathogenic fibrils. Although MPTP treatment in rodents induces important signs of 
disease-like loss of dopaminergic neurons and a diminished performance in motor-
performance tests, the central sign of human α-synuclein pathology, formation of LBs is 
still lacking (Beal, 2001; Maries et al., 2003; Meredith et al., 2002). Administration of the 
pesticide rotenone can evoke similar PD-associated pathophysiological signs, with α-
synuclein inclusions that structurally resemble LBs more closely than in the MPTP model 
(Betarbet et al., 2000). Although the neurotoxic models can mimic key features of PD-
associated neurodegeneration, these models are limited since they do not recapitulate the 
progressive nature of disease or non-motor symptoms that are characteristic for 
synucleinopathies (Dawson et al., 2002). 
 
1.5.2 Transgenic mouse models 
The normal cellular function of α-synuclein has been investigated in knockout mice 
deficient for α-synuclein. Mice with a complete knockout of α-synuclein were viable, did 
not show morphological abnormalities, but showed changes in the metabolism of 
dopamine indicating a role for α-synuclein as negative regulator in dopamine 
neurotransmission (Abeliovich et al., 2000). On the other hand, mice overexpressing 
human wild-type α-synuclein in neurons under control of the platelet-derived growth 
factor-β (PDGF- β) promoter develop α-synuclein inclusions, lose striatal dopaminergic 
terminals and show diminished motor performance (Masliah et al., 2000). Mutations of 
α-synuclein that cause familial PD have been used to establish further transgenic mouse 
models. For instance, overexpression of the A30P or A53T mutation under control of the 
promoter for tyrosine hydroxylase (TH) or the prion protein (PrP) promoter have been 
used to study pathophysiological features. Targeting the nigrostriatal pathway by use of 
the TH promoter indicated that overexpression of α-synuclein within dopaminergic 
neurons is not sufficient to cause LB pathology and neurodegeneration (Matsuoka et al., 
2001). Using the promoter for PrP, which is naturally expressed in neurons led to a more 
pronounced disease phenotype with loss of dopaminergic neurons, behavioral deficits and 
clear formation of α-synuclein inclusions that were accompanied by signs of 
neuroinflammation (Giasson et al., 2002; Lee et al., 2002).  
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1.6 The role of the nose in neurodegenerative diseases 
There is some evidence that environmental factors like toxins and chemicals that enter 
the nasal tracts of humans or rodents could cause or contribute to neurodegeneration 
(Calderon-Garciduenas et al., 2008; Levesque et al., 2011). The olfactory bulb was 
described as the first brain region where pathological lesions appear in idiopathic PD. Its 
dysfunction is accompanied by hyposmia and anosmia as one of the first non-motor 
symptoms during disease progression (Braak et al., 2003a; Braak et al., 2003b; Weintraub 
et al., 2008). These findings support the “olfactory vector hypothesis”, which assumes 
that environmental agents might be able to reach the brain by passing the olfactory 
epithelium and could accelerate or even initiate the progression of pathology (Doty, 2008; 
Prediger et al., 2012). Airborne particles might enter the olfactory epithelium and become 
absorbed from the non-myelinated nerve endings of the olfactory cilia that are located in 
the olfactory mucosa (Fig. 1.5). The olfactory cilia proceeding into sensory receptor 
neurons that pass through the cribriform plate to reach the olfactory bulb.  
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Fig. 1.5 The olfactory system in rodents. A) Schematic view through a rodent head, indicating the 
vomeronasal organ (VNO), the main olfactory epithelium (MOE), the main olfactory bulb (MOB) and the 
accessory olfactory bulb (AOB). B) Schematic view through the MOE and its peripheral interconnections 
to the olfactory bulb (adapted Mombaerts, 2004,with permission from Nature Publishing Group). 
 
 
In CJD patients PrPSc accumulates in the olfactory cilia and basal cells in the olfactory 
mucosa. This shows that these cells are susceptible to prion replication (Zanusso et al., 
2003). The nasal cavity as route for prion infection has been confirmed by the extranasal 
inoculation of hamsters with transmissible mink encephalopathy (TME) prions that 
accumulated in the nasal-associate lymphoid tissue (Kincaid and Bartz, 2007). In 
addition, the direct intracerebral injection of TME prions into the olfactory bulb could 
confirm prion replication in neurons of the olfactory bulb, in olfactory receptor neurons 
(ORNs) and vomeronasal receptor neurons (VRNs) (Bessen et al., 2010). Accordingly, 
when transgenic Tg(cerPrP) mice expressing cervid PrPC were exposed to CWD-derived 
aerosols, they efficiently entered the olfactory epithelium and caused disease (Denkers et 
al., 2010). Since aerosols are naturally generated solid or liquid particles dispersed in the 
air, like dust or air pollutants, further studies concerning their infectivity in 
neurodegeneration is of great interest (Stitz and Aguzzi, 2011).
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1.7 Objectives 
The general objective of this work is to understand whether disease-associated α-
synuclein can neuroinvade the CNS and initiate progressive disease via similar 
mechanisms and peripheral routes as shown for prions. By using a reporter mouse model 
for GFAP, the progressive α-synuclein pathology can be correlated to neuroinflammation. 
In this respect this thesis pursues the following specific objectives:  
1) To evaluate the virulence pattern of neuropathology induced by intracerebral and 
intraglossal injection of recombinant mouse α-synuclein fibrils 
2) To investigate whether a mouse model overexpressing the A53T mutant of α-
synuclein is susceptible to develop neuropathology after peripheral injection of 
recombinant human α-synuclein fibrils via the tongue or the peritoneum 
3) To test the ability of aerosols derived from MSA brain homogenate to enter the 
brain via nasal passages and induce neuropathology  
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2 Materials and Methods 
2.1 Animals  
Inoculation experiments were performed in hemizygous Tg(Gfap-luc+/-) mice and 
hemizygous bigenic Tg(M83+/-:Gfap-luc+/-) mice at an age of six-to-eight weeks. 
Tg(Gfap-luc+/-) mice express firefly luciferase under control of a murine Gfap (Glial 
fibrillary acidic protein) promoter on a FVB background (Fig. 2.1). The Gfap-controlled 
expression of the firefly luciferase allows monitoring of astroglial activation, which 
correlates with neuroinflammation and neuronal damage (Zhu et al., 2004). Tg(M83+/-
:Gfap-luc+/-) mice were bred by intercrossing homozygous Tg(Gfap-luc+/+) mice together 
with homozygous Tg(M83+/+) mice (according the Jackson Laboratory also termed as 
B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J mice), which highly express the A53T mutant of 
human α-synuclein on a C57/BL6 background from the prion protein promoter (Giasson 
et al., 2002). All mice were housed under standard conditions with a 12 h light/dark cycle 
and free access to food and water. Animal care and experiments were performed 
according to protocols approved by the animal protection committee of the North Rhine-
Westphalia State Environment Agency (LANUV). 
 
 
Fig. 2.1 Schematic view of the firefly luciferase reporter gene construct. The luciferase gene 2 (Luc2) 
is driven from a Gfap promoter and has a hemoglobin beta intron 2 (Hbb) as an adapter. Activation of the 
Gfap promoter initiates expression of luciferase, which catalyzes the oxidative decarboxylation of its 
substrate luciferin into oxyluciferin wherby a bioluminescence signal is emitted.  
 
 
2.1.1 Genotyping 
Presence of the firefly luciferase transgene in the offspring of the Tg(Gfap-luc+/-) and 
Tg(M83+/-:Gfap-luc+/-) mice was determined by standard PCR by amplifying  a 1 kb 
sequence within the Gfap-luc transgene. Primer sequences and cycling conditions used 
for PCR are listed in Table 2.1 and Table 2.2.  
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Table 2.1 PCR primers 
Primer Sequence 5` to 3` Primer Type 
Luc 1 TGG ATT CTA AAA CGG ATT ACC AGG G forward 
Luc 2 CCA AAA CAA CAA CGG CGG C reverse 
 
Table 2.2 PCR cycling conditions 
 Step Cycles Temperature 
in °C 
Time 
Denaturation 1 1 97 5 min 
Denaturation 2 
35 
94.5 40 s 
Annealing 3 58 90 s 
Extension 4 72 90 s 
 5 1 72 10 min 
 
 
 
The transgene encoding human α-synuclein with the familial A53T mutation was verified 
by real time PCR. Therefore, animal DNA was extracted from tail biopsies using the 
DNeasy Blood and Tissue Kit (Qiagen). Shortly, the tail tips were completely lysed in a 
Proteinase K containing buffer at 56 °C for 1 h and the insoluble components were 
separated by centrifugation for 2 min at 6000 x g. Lysates were loaded on silicia-
membrane spin columns, purified by two washing steps and eluted in 40 μL distilled 
water. After the photometric quantification 90 ng of DNA was used for each real-time 
PCR reaction and samples were in triplicates. To follow the amplification reaction 
fluorescently labeled DNA oligonucleotides that bind downstream to one of the primers 
were used. In addition an internal positive control was carried along. Primers that were 
used for the amplification of the transgene, the internal positive control, and the 6-FAM 
-and Cyanine-5-labeled oligonucleotides are listed in Table 3. To normalize the 
fluorescent reporter signal a ROX reference dye (Thermo Fisher Scientific) was used. 
The fluorescence signal was measured in a 7900 HT Fast Real Time PCR system (Thermo 
Fisher Scientific) according to the cycling conditions listed in Table 2.4. 
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Table 2.3 Real-time PCR primers 
Primer Sequence 5` to 3` Primer type 
oIMR1544 CAC GTG GGC TCC AGC ATT internal positive control 
(forward) 
oIMR3580 TCA CCA GTC ATT TCT GCC TTT G internal positive control 
(reverse) 
oIMR1770 TGA CGG GTG TGA CAG CAG TAG transgene 
oIMR1771 CAG TGG CTG CTG CAA TG  
 
transgene 
TmoIMR0025 [6FAM] CCC TGC TCC CTC CAC TGT CTT CTG G 
[BHQ1] 
transgene probe 
TmoIMR0105 [Cyanine5] CCA ATG GTC GGG CAC TGC TCA A 
[BHQ3] 
internal control probe 
 
Table 2.4 Cycling conditions for the Real time PCR 
 Step Cycle Temperature 
in °C 
Time 
Pre-denaturation 1 1 95 3 min 
Denaturation 2 
40 
95 5 s 
Extension 3 60 30 s 
 
 
 
2.2 Inoculum preparation 
2.2.1 Prion strains 
The RML (Rocky Mountain Laboratory) prions were diluted from a 10 % stock 
concentration to a 0.2 % concentration in Ca2+-and Mg2+-free PBS with 5 % BSA 
(Thermo Fisher Scientific) under addition of 0.5 U/mL penicillin and 0.5 µg/mL 
streptomycin (Sigma).  
 
2.2.2 Preparation of recombinant mouse α-synuclein fibrils 
Recombinant mouse full-length wild-type α-synuclein (MyBioSource) in glycerol buffer 
(20mM Tris-HCl with pH 7.5, 10 % glycerol) was dialyzed against TBS aggregation 
buffer (20 mM Tris-HCl with pH 7.2, 150 mM NaCl with pH 7.2) through a 
semipermeable Slide-A-Lyzer dialysis cassette with a 3.5 kDa cut-off (Life Technology). 
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To reach a final concentration of 3 mg/mL the α-synuclein protein was concentrated in 
Amicon Ultra Tubes 3K (Millipore) by centrifugation. For fibril assembly 3 μg/μL protein 
was agitated together with one glass bead (VWR) in an orbital thermomixer (Eppendorf) 
at 800 rpm and 37 °C for a period of 5 days. Prior to injection, the harvested fibrils were 
diluted to 1 ug/uL in Ca2+ -and Mg2+-free PBS and sonicated on ice for 1 min with a pulse 
of 1 s using a Sonoplus mini20 sonicator (Bandelin). 
 
2.2.3 Preparation of recombinant human α-synuclein fibrils 
The expression and purification of the recombinant human α-synuclein protein was 
conducted by Dr. Julius Tachu Babila at the German Center of Neurodegenerative 
Diseases, Bonn. Fibrils of the human wild-type α-synuclein were prepared as previously 
described in (Breid et al., 2016). Briefly, E. coli cells harboring the pET-3a expression 
plasmid (Novagen) for α-synuclein were grown at 37 °C in 1 L LB medium containing 
ampicillin, chloramphenicol, and 1 % glucose to an OD600 of 0.5. Protein expression 
was induced by 0.1 mM IPTG and the bacteria were grown for 5 h at 37 °C. Periplasmatic 
material was released into the buffer by an osmotic shock. Cells were pelleted by 
centrifugation at 6000  g for 15 min, resuspended in a 35 % sucrose solution with 2 mM 
EDTA and 30 mM Tris-HCl (pH 7.2) and incubated for 15 min under shaking at RT. The 
cells were again harvested and resuspended in ice-cold water containing 5 mM MgSO4. 
The periplasmatic material was boiled for 20 min and then centrifuged at 5000  g for 30 
min to subject the supernatant to fractional ammonium sulfate precipitation. Briefly, 
(NH4)2SO4 crystals were added over 10 min to the supernatant to reach a 35 % saturation 
(19.4 g/ 100 mL) with gentle stirring on ice. Afterwards the centrifugation was repeated. 
Then 11.8 g/100 mL of (NH4)2SO4 crystals were added over 10 min to take the 
concentration from 35 % to 55 % saturation with gentle stirring on ice. Finally the 
centrifugation was repeated. The pellet was re-suspended in 10 mL water and dialyzed 
three times for 3 h against 20 mM Tris-HCl (pH 8.0). α-Synuclein was purified from the 
supernatant by Resource Q anion exchange chromatography using 20 mM Tris-HCl (pH 
8.0) as binding buffer and 500 mM NaCl in 10 mM Tris-HCl (pH 8.0) as elution buffer 
on an ÄKTA pure chromatography system (GE Healthcare). α-Synuclein was released 
from the column using a 30 mL linearly increasing gradient from the binding buffer 
towards the elution buffer and dialyzed against 150 mM NaCl in 20 mM Tris-HCl (pH 
7.2). Fibril assembly for α-synuclein was performed in an orbital thermomixer 
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(Eppendorf) agitating 3 μg/μL protein at 800 rpm and 37 °C for 5 days. Prior to the 
injection, the fibrils were diluted in Ca2+-and Mg2+-free PBS to 1 μg/μL and sonicated for 
1 min with a pulse of 1 s using a Sonoplus mini20 sonicator (Bandelin). 
 
2.2.4 Preparation of MSA brain homogenate  
Frozen brain tissue from the cortex of an MSA patient was homogenized in Ca2+-and 
Mg2+-free PBS (pH 7.4) by two 30 s cycles in a Precellys 24-Dual homogenizer (Peqlab) 
under addition of protease and phosphatase inhibitors (HALT Protease and Phosphatase 
Inhibitor Cocktail, Thermo Fisher Scientific). Initially a concentration of 50 % (w/v) 
homogenate was generated and further diluted into 20 %, 10 %, 5 % and 1 % (w/v) 
homogenates. 
 
2.3 Transmission studies 
2.3.1 Transmission by intracerebral injection 
Mice were intracerebrally inoculated by a stereotactic surgery using a three-dimensional 
coordinate system (Kopf) to target the injection site. Animals were shortly anaesthetized 
in a gas anesthesia induction chamber using an isofluran/oxygen gas mixture at a flow 
rate of 3 L/min. After shaving the scull of the anesthetized mouse, the animal was placed 
in a head frame lying on a heated pad at 37°C. To fasten the position of the head the 
mouse was secured by two ear bars. Once the animal’s head was in a defined position, 
the mouth was connected to the anesthesia tube with an isoflurane/oxygen flow rate of 2 
L/min. To prevent dryness, the eyes were covered with Vaseline ointment (Molyduval). 
The scalp was opened by making a midline incision with an one-way scalpel (NeoLab). 
After cleaning the surgery area with Cutasept desinfection spray (Roth), a 27-gauge 
disposable hypodermic syringe (VWR) prepared with the inoculum was installed at the 
holding arm. The manipulator arm holding the syringe was moved along the three-
dimensional coordinates to reach the striatum using the sutures and the bregma as 
anatomical landmarks (Fig. 2.2) (Cetin et al., 2006). 
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Injection coordinates for the striatum: 
+ 0.2 mm in anterior-posterior direction relative to the bregma 
+ 2.0 mm in medial-lateral direction relative to the sagittal suture 
+ 2.6 mm in dorso-ventral direction through the cranium 
 
 
Fig. 2.2 Plan view to the cranium of a mouse. The anatomical point were the sagittal and the coronal 
sutures intersect each other is called the bregma and is localized in the rostral part of the cranium. The 
lambda is the anatomical point where the lambdoid suture crosses the sagittal suture in occipital orientation 
(Cetin et al., 2006). 
 
 
First, the syringe was installed above the bregma and then moved to its appropriate 
position as indicated by the injection coordinates. To reach the + 2.6 mm dorso-ventral 
position, the needle was injected into the cranium. After a short adaption time of 1 min, 
the plunger of the syringe was shortly and gently pushed to carefully release the inoculum. 
For a better absorption and to avoid the loss of inoculum, an adaption pause of 3 min 
between every inoculum release was kept. After complete release of the inoculum, the 
syringe was left in place for another 15 min before it was removed and the scalp sutured 
with a veterinary tissue adhesive (3M Vetbond). To minimize local inflammation at the 
injection site, the animals received 15 μL antibiotics (Borgal solution 24%) into the scalp 
and the suture was treated with an antiseptic cream (Betaisodona). In addition, the mice 
received an intraperitoneal injection of 15 μL Carprofen as an analgesic (Rimadyl). 
Postoperative care also included injection of 300 μL 5% glucose solution (Braun) and 
300 μL 0.9 % physiologic salt solution (Braun) into the peritoneum. Finally, the mice 
were constantly monitored, still lying on a heated pad, until they had completely 
recovered. 
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2.3.2 Transmission by intraglossal injection 
Mice were anaesthetized by an intraperitoneal injection with ketamine and xylazine (100 
mg/kg for ketamine 2 % and 10 mg/kg for xylazine 10 %, Ratiopharm) according to their 
body weight. The anesthesized animals were turned upside down and fixed on a heated 
pad using adhesive tape. To make the inner bottom side of the tongue accessible the 
mouth of the animal was opened with two forceps (FST) and by holding the tongue with 
another forceps the tongue was pulled forward. A 27-gauge disposable hypodermic 
syringe (VWR) was used to inject 5 µg of the recombinant mouse α-synuclein (1 µg/µL) 
or 10 µg of the recombinant human α-synuclein (2 µg/µL) and slowly injected into the 
right bottom side of the tongue in proximity to the right strand of the hypoglossal nerve. 
After a short adaption time of 5 s the needle was carefully retracted. Animals lying on a 
heated pad were constantly monitored until they had recovered completely.  
 
2.3.3 Transmission by intraperitoneal injection 
For injecting into the peritoneum the animals were shortly narcotized in an 
isoflurane/oxygen chamber at a flow rate of 2 L/min and injected with 50 µg of 
recombinant human α-synuclein using a 27-gauge disposable hypodermic syringe. The 
animals were monitored until they had completely recovered. 
 
2.3.4 Inhalation 
Mice were exposed to aerosols with pathological human α-synuclein derived from the 
brain of an MSA patient using a home-made inhalation chamber (Fig. 2.3). The exposure 
chamber was made of a plastic container with 7 holes with a diameter of 3 cm that were 
drilled into the sidewalls. Six 50 mL tubes (Nerbe plus) with space for six mice were 
inserted and sealed with a hot melt glue gun (Conrad). To allow nasal exposure of the 
animals the tube tips were cut off.  The inhalation container was stabilized with additional 
tubes functioning as legs. The nebulizer device (Pari Boy SX, Pari) was connected to the 
7th hole. Additionally, a filter unit (Sterivex, Millipore) was inserted into the container lid 
as an air vent trapping excessive aerosolized particles. To ensure its proper closure, 
clamps (Conrad) were clipped around the chamber. To prevent mice from changing their 
position within the tube, animals were fixated by addition of tissue paper before capping 
tubes. Animals were exposed to aerosols made from 1 mL PBS or MSA brain homogenate 
that was previously diluted to 20 %, 10 %, 5 %, 10 % or 1 % (w/v) in PBS. The nebulizer 
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device operates with a pressure of 1.6 bar and generates particles with a mass median 
diameter of 2.2 μm. During an exposure time of 10 min the animals inhaled aerosols by 
normal breathing trough the nasal tracts. After inhalation animals were carefully released 
from the tubes and returned to their cages. 
 
 
 
Fig. 2.3 Inhalation chamber to expose mice to aerosols. The home-made inhalation chamber is connected 
to a nebulizer system (Pari Boy SX, Pari). 
 
 
2.4 Bioluminescence imaging 
For the non-invasive visualization of the bioluminescence signal from the brains of the 
Tg(Gfap-luc+/-) and bigenic Tg(M83+/-:Gfap-luc+/-) mice. Animals were imaged once a 
week or every two weeks using an IVIS Lumina II imaging system (Caliper). Prior to 
imaging, the heads of mice were shaved and depilated with a special depilatory cream 
(Veet). To reduce an unspecific bioluminescence signal, the ears were colored in black 
using a non-irritating lab marker (Securline). Beforehand mice were shortly narcotized in 
an isoflurane/oxygene chamber with a flow rate of 2 L/min. The D-luciferin potassium 
salt (Acris) as substrate of the luciferase was dissolved in Ca2+-and Mg2+-free PBS to give 
a 30 mg/mL stock solution and intraperitoneally injected at 150 mg D-luciferin per 
kilogramm body weight. After 10 min incubation the animals were placed under 
continuous anesthesia into the imaging chamber. The emitted light was captured by a 
sensitive CCD camera for an exposure period of 60 s. BL emitted from the brain was 
quantified with Living Imaging 3.0 Software (Perkin Elmer). 
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2.5 Negative stain electron microscopy  
The negative stain electron microscopy was conducted by Karen Tolksdorf at the 
department of neurology of the University of Bonn (Fig. 3.1A) and by Maria C.Garza and 
Dr. Holger Wille at the University of Alberta, in Edmonton, Alberta (Fig. 3.10A) (Breid 
et al., 2016). Transmission electron microscopy was performed with a Tecnai F20 TEM 
(FEI Company) operating at an acceleration voltage of 200 kV. Five μL sample were 
adsorbed for 30 s onto freshly glow discharged formvar/carbon coated 200 mesh copper 
grids. The grids were washed briefly with 0.1 M and 0.01 M ammonium acetate buffer 
(pH 7.4) and then stained with two 50 μL drops of freshly filtered 2% (w/v) uranyl acetate. 
The grids were allowed to dry overnight before viewing. The electron micrographs were 
recorded on an Eagle 4K CCD camera (FEI Company). Three different preparations of 
α-synuclein were characterized by thoroughly inspecting at least five different areas per 
grid.  
 
2.6 Biochemical analysis 
2.6.1 Purification of detergent-insoluble proteins  
2.6.1.1 Extraction of sarcosyl-insoluble proteins  
To collect brains, spinal cords, and tongues mice were shortly narcotized with isoflurane 
and killed by a spinal dislocation. Organs were dissected, snap-frozen on dry ice and 
stored at -80°C. For further processing, brain or spinal cord samples were homogenized 
and diluted (w/v) in Ca2+ -and Mg2+-free PBS (pH 7.4) to a final concentration of 10% 
(w/v). Under addition of benzonase nuclease (Sigma) as well as protease and phosphatase 
inhibitors (HALT Protease and Phosphatase Inhibitor Cocktail, Thermo Fisher Scientific) 
the tissue was homogenized by two 30 s cycles with 6,000 rpm in a Precellys 24-Dual 
homogenizer (Peqlab). Tongues were also homogenized in PBS under addition of 
benzonase nuclease (Sigma) as well as protease and phosphatase inhibitors (HALT 
Protease and Phosphatase Inhibitor Cocktail, Thermo Fisher Scientific) to a final 
concentration of 10 % (w/v) by four 30 s cycles with 6,000 rpm in the Precellys 24-Dual 
homogenizer. To ensure that all cells were disrupted, all samples were sonicated twice 
for 10 s using a Sonoplus mini20 sonicator (Bandelin). After adjusting homogenates to 
750 mM NaCl, they were centrifuged at 1,000  g for 5 min at 4 °C to separate tissue 
debris. Protein concentration was determined by using the Pierce BCA Protein Assay 
(Thermo Fisher Scientific). One thousand μg of brain and tongue homogenates and           
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800 μg of the spinal cord homogenate were incubated on ice for 15 min with N-
lauroylsarcosyl (Sigma) at a final concentration of 10 % (w/v). Homogenates were 
ultracentrifuged at 465,000  g for 1 h at 4 °C over a 3 mL 10% (w/v) sucrose cushion in 
a TLA-110 rotor (Optima Max-XP, Beckman Coulter). The resulting pellets were 
resuspended in 45 µL of TD4215 denaturing buffer containing 4 % SDS, 2 % β-
mercaptoethanol, 192 mM glycine, 25 mM Tris, and 5 % (w/v) sucrose. For heat 
denaturation samples were boiled at 100 °C for 5 min and loaded onto 4-12 % NuPage 
gels (Thermo Fisher Scientific) as previously described (Betemps et al., 2014). The 
further processing is described in 2.6.2. 
 
2.6.1.2 Extraction of Triton X-100 and sarcosyl-insoluble proteins  
To characterize the MSA brain homogenate that was used for inhalation experiments, the 
tissue was homogenized and diluted in Ca2+ -and Mg2+-free PBS to reach a 50% (w/v) 
solution. After addition of benzonase nuclease (Sigma) as well as phosphatase and 
proteinase inhibitors (HALT Protease and Phosphatase Inhibitor Cocktail, Thermo Fisher 
Scientific), homogenates were sonicated twice for 10 s with a Sonoplus mini20 sonicator 
(Bandelin) and once for 10 min in a sonicator water bath (Bandelin). For buffer exchange, 
proteins were pelleted by ultracentrifugation at 100,000 x g for 30 min at 4°C and 
subsequently dissolved by vortexing in a Triton buffer containing 10 mM Tris-HCl (pH 
7.4), 0.8M NaCl, 1 mM EGTA, 10 % sucrose and 1 % Triton X-100 (Sigma), sonicated 
for 10 min in a water bath and shaken in a thermocycler for 30 min at 37 °C at 800 rpm. 
Insoluble proteins were pelleted by ultracentrifugation at 100,000 x g for 30 min at 4 °C 
and again dissolved by vortexing in a sarcosyl buffer containing 10 mM Tris-HCl (pH 
7.4), 0.8 M NaCl, 1 mM EGTA, 10 % sucrose and 1 % sarcosyl. Following another 
sonication step for 10 min in a water bath, proteins were shaken in a thermocycler for 30 
min at 37 °C at 800 rpm. Finally samples were spun at 100,000 x g for 30 min and 
dissolved in Tris-HCl (pH 7.4) as previously described (Masuda-Suzukake et al., 2013). 
 
2.6.2 Immunoblotting (SDS-PAGE) 
For immunoblotting protein samples were resuspended in loading dye (New England 
BioLabs) and heat denatured at 100°C for 5 min. Denatured protein samples were loaded 
onto a NuPAGE 4-12 % Bis-Tris gel (Thermo Fisher Scientific) and further separated in 
a morpholineethanesulfonic acid (MES) buffer system (Thermo Fisher Scientific). 
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SeeBlue plus 2 pre-stained standard (Invitrogen) or Chameleon duo pre-stained protein 
standard (LI-COR Biosciences) were used as protein ladders. Proteins were separated by 
gel electrophoresis at 100 V and transferred onto PVDF membranes with a pore size of 
0.45 μm (Millipore) by use of a semidry blotting system (Hoefer). After blotting for 1 h 
at 120 V, membranes were incubated in 0.4 % (v/v) formalin solution with Ca2+ -and 
Mg2+-free PBS for 30 min on a rotor at RT to cross-link the proteins with the membrane. 
Membranes were blocked in a buffer containing TBS with 0.05 % (v/v) Tween 20 (MP 
Biomedicals) and 5 % (w/v) milk for 1 h under rotation at RT. Subsequently, the 
immunoblots were probed with a primary antibody diluted in blocking buffer overnight 
at 4 °C. For detection of the primary antibody a horseradish peroxidase-conjugated 
secondary antibody (Cayman) or an IRDye-conjugated antibody (LI-COR Biosciences) 
was incubated for 1 h at RT. The chemiluminescent reaction for the HRP antibodies was 
visualized with SuperSignal West Dura Extended Duration Substrate (Thermo Fisher 
Scientific) in a chemiluminescence reader (Stella, Raytek). To detect the fluorophore-
conjugated secondary antibodies fluorescence was visualized with the Odyssey infrared 
imaging system (LI-COR Biosciences). 
 
2.7 Immunohistochemistry  
For immunohistochemical analysis mice were shortly anesthetized with isoflurane and 
transcardially perfused with 0.9 % NaCl solution followed by a 4 % paraformaldehyde 
buffer solution (Sigma) by using a perfusion pump (Ismatec). After removing the brain 
and the tongue, tissues were transferred into a 10 % PFA solution and incubated at 4°C 
overnight. For long-term storage all tissues were transferred into a 1 % PFA solution and 
kept at 4°C. To avoid over-fixation spinal cords were directly transferred into a 70 % 
EtOH bath and kept at 4 °C. For further processing, fixed mouse brains were sliced into 
four to five sections using an adult mouse brain matrix for coronal sectioning (WPI) (Fig. 
2.4). In addition, mouse tongues were sliced into four coronal sections and spinal cords 
were separated in 6-8 short coronal parts. Tissue sections were dehydrated by a series of 
graded ethanol baths (70 %, 95 %, 100 %, 100 %, 100 %, 100 % EtOH), transferred into 
two xylol baths and finally infiltrated with paraffin waxes using a tissue processing station 
(Leica Biosystems). Tissue sections of brain, tongue, and spinal cord were embedded into 
tissue processing cassettes (Roth) under use of a paraffin station (Leica Biosystems). 
Embedded brains were cut into 8 μm and tongues cut into 5 μm coronal sections by using 
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a microtome (Leica) and mounted on adhesive Super Frost Plus glass slides (Schubert 
and Weiss).  
  
 
 
Fig. 2.4 Sectioning of the mouse brain. After fixation in paraformaldehyde brains were sliced into five 
parts to facilitate its infiltration with paraffin waxes. Embedded brain sections were further cut into 8 μm 
coronal sections (Franklin and Paxinos, 2008). 
 
 
2.7.1 DAB staining 
Brain sections were mounted on glass slides and incubated for 10 min at 60°C to melt the 
paraffin that surrounds the tissue. For deparaffinization the tissue was soaked in two xylol 
(Sigma) baths, transferred to an isopropanol/xylol bath for 5-10 min and rehydrated 
through a series of graded ethanol baths (100 %, 90 %, 70 %, 50 %, H2O) with an 
incubation time of 5 min for each step. For antigen retrieval sections were incubated in 
citrate buffer for 10 min at RT and than cooked in a heated citrate buffer (pH 6.0) bath 
for 10 min in a microwave oven at 650 W. After cooling down, slides were transferred to 
a PBS bath for 10 min and further incubated with a 3 % hydrogen peroxide solution 
(Sigma) for 30 min to inhibit the endogenous peroxidases. After washing in PBS for 10 
min and drawing a line around the tissue section with a hydrophobic barrier pen (Biozol 
Diagnostica), sections were blocked for 1 h at RT in blocking buffer containing 20 % 
(v/v) normal goat serum, 1 % (v/v) BSA (Thermo Fisher Scientific) and 0.5 % Triton X-
100 (Sigma). The primary antibody diluted in 1 % (v/v) normal goat serum, 1 % (v/v) 
BSA, and 0.25 % Triton X-100 in PBS was incubated overnight at 4 °C. The antibodies 
used in this study with corresponding dilutions are listed in Table 2.5. To avoid drying of 
tissue sections the slides were stored in a wet chamber. After washing once with 0.25 % 
(v/v) Triton X-100 in PBS and twice with PBS sections were incubated with a secondary 
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peroxidase-conjugated antibody using the Vectastain ABC kit (Vector Laboratories) for 
rabbit antibodies and the MOM kit (Vector Laboratories) for mouse antibodies. For 
visualization sections were incubated in DAB (3-3’-diaminobenzidine, Biozol 
Diagnostica). Therefore the chemical was incubated for 30-60 s and reactions were 
inactivated in a 3 % hydrogen peroxide bath. After three washing steps for 10 min in 
distilled water acidic/negative charged structures like the DNA-containing nucleus were 
counterstained with Haematoxylin QS (Vector Laboratories) for 40 s. Slices were 
thoroughly washed in distilled water and bedewed with Vectamount mounting medium 
(Biozol) before they were covered with glass slides (Roth). After drying overnight at RT 
the slides were scanned on an Axio Scan.Z1 scanner (Carl Zeiss) and analyzed with the 
ZEN lite software (Carl Zeiss). 
 
2.7.2 Fluorescence staining 
Paraffin-embedded brain sections were incubated for 10 min at 60°C to melt the paraffin. 
Subsequently, sections were deparaffinized in two xylol and one isoprobanol/xylol bath 
for 5-10 min and finally hydrated through a series of graded ethanol baths (100 %, 90 %, 
70 %, 50 %, H2O). For antigen retrieval tissue sections were incubated for 5 min in citrate 
buffer and additionally boiled for 10 min at 650 W in a microwave oven. After the slides 
had cooled down for 20 min they were rinsed with PBS for 10 min. To minimize the 
antibody amount used, a hydrophobic barrier was drawn around the tissue sections 
(Biozol Diagnostica). Afterwards, sections were incubated for 1 h at RT in blocking 
buffer containing 20 % (v/v) normal goat serum, 1 % (v/v) BSA and 0.5 % Triton X-100. 
Sections were incubated with primary antibody diluted in 1 % (v/v) normal goat serum, 
1 % (v/v) BSA, and 0.25 % Triton X-100 in PBS overnight at 4°C inside a wet chamber. 
The antibodies used in this study with corresponding dilutions are listed in Table 2.5. 
Slides were washed once with 0.25 % (v/v) Triton X-100 in PBS and twice with PBS for 
20 min. Thus, tissue sections were stained with Alexa Fluor 488- or Alexa Fluor 594-
conjugated (Thermo Fisher Scientific) anti-mouse or anti-rabbit secondary antibodies and 
the nuclear dye DAPI (4’,6-diamidino-2-phenylindole, Thermo Fisher Scientific) diluted  
in 1 % (v/v) normal goat serum (Thermo Fisher Scientific) and 1 % (v/v) BSA in PBS for 
1 h at RT. Secondary antibodies were used at a 1:1,000 working dilution and DAPI was 
diluted 1:50,000. After washing once with 0.25 % (v/v) Triton X-100 in PBS and twice 
with PBS for 10 min, slides were mounted with Fluoromount media (Omnilab) and 
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covered with glass slides (Roth). Finally, the slides were visualized with an LSM 700 
confocal laser scanning microscope using the ZEN software (Carl Zeiss). 
 
 
 
 
Table 2.5 Antibodies used for immunofluorescence (IF), immunohistochemistry (IHC) and western  
                 blotting (WB)               
 
 
 
Antigen 
(antibody clone) 
Source Host Immunogen 
Dilution 
for IHC/IF 
Antigen 
retrieval 
Dilution 
for WB 
Actin C4 Abcam mouse - - - 1:1000 
p-α-Synuclein (phospho 
Ser 129) 81A 
Covance mouse pSer129 1:200 
citrate 
buffer 
- 
p-α-Synuclein (phospho 
Ser 129) pSyn #64 
Wako mouse pSer129 1:1200 
citrate 
buffer 
- 
p-α-Synuclein (phospho 
Ser 129) EP1536Y 
Abcam rabbit pSer129 - - 1:1000 
human α-Synuclein 
Syn 211 
Millipore mouse 121-125 1:100 
citrate 
buffer 
 1:2000 
mouse α-Synuclein 
D37A6 
Cell 
signaling 
rabbit 103-110 1:100 
citrate 
buffer 
1:1000 
Choline 
acetyltransferase 
(ChAT) 
Millipore rabbit - 1:100 
citrate 
buffer 
- 
Glial fibrillary acidic 
protein (GFAP) 
 
Dako 
 
 
rabbit 
 
- 1:200 
citrate 
buffer 
- 
Iba 1 Wako rabbit - 1:500 
citrate 
buffer 
- 
 
Sequestosome 1 (p62) 
 
Proteintech 
 
rabbit 
 
- 1:100 
citrate 
buffer 
- 
Tyrosine hydroxylase Abcam rabbit - 1:750 
citrate 
buffer 
- 
Ubiquitin 1 Ubi-1 Millipore mouse - 1:500 
citrate 
buffer 
- 
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2.8 Behavioral analysis 
To evaluate changes in the motor behavior, balance, coordination and grip strength of 
injected animals, their rotarod and wire-hang performance was tested after 30, 90, 180, 
270, and 400 days post inoculation (dpi). 
 
2.8.1 Rotarod test 
A rotarod treadmill (Med associates) was used to assess motor learning, balance and 
coordination of the injected animals. Mice were tested four times per day on four 
consecutive days. Before each run the treadmill was cleaned with 70 % ethanol to 
minimize odor cues. Each mouse was placed on the horizontal rod, which accelerated 
speed from 4-400 rpm. The latency to fall was measured during a period of 5 min. 
Between each run the mice had 10 min time to recover. The first run on each day was 
considered a training session and not scored (Fig. 2.5). For the calculation of the running 
performance the training session at day one was considered as basal performance (= 100 
% latency to fall) and the runs from the consecutive days were referred to them. 
 
2.8.2 Wire-hang test 
The neuromuscular strength of the injected animals and their balance were assessed by 
the wire-hang test. Previous to each testing the wire grids were disinfected with 70 % 
ethanol to minimize odor cues. Once the animal was placed on the wire grid the grid was 
slightly shaken to ensure that the animal gripped the wire. The time measurement started 
with the upside down turning of the wire grid. The latency to fall was measured with 
maximal 300 s as cut-off time. The mice were tested throughout one day with 5 hanging 
runs and with a regeneration time of 10 min between each trial. The first and second runs 
were considered as training sessions and the runs 3-5 were included to the calculation of 
the mean hanging performance (Fig. 2.5). 
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Fig. 2.5 Overview about the testing protocols used for behavioral assays. A) The four-day protocol for 
the rotarod-performance test considered the entire first day and the first run of each consecutive day as 
training. To calculate the mean latency to fall, runs 2-4 on day two, three, and four were scored. B) For the 
wire-hang test animals were tested on a single day while the first two of five total sessions were considered 
as training. The mean of sessions 1-3 was calculated as the animals hanging performance for that day. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A)  Rotarod performance-test protocol 
Training 1 Training 1 Training 1 Training 1 
Training 2 Run 2 Run 2 Run 2 
Training 3 Run 3 Run 3 Run 3 
Training 4 Run 4 Run 4 Run 4 
B) Wire hang test 
protocol 
Training 1 
Training 2 
Run 1 
Run 2 
Run 3 
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3 Results 
3.1 Virulence of recombinant mouse α-synuclein fibrils injected 
into Tg(Gfap-luc+/-) mice 
3.1.1 Intracerebral injection with α-synuclein fibrils evoked mild 
neuropathology  
To address whether intrastriatal injection of aggregated α-synuclein can induce 
widespread synucleinopathy in the brain, Tg(Gfap-luc+/-) reporter mice were inoculated 
with recombinant mouse wild-type α-synuclein fibrils (Appendix Fig. 5.2 A). The 
visualization of the inoculum showed dot-like oligomeric and rod-shaped fibrillar forms 
of α-synuclein (Fig. 3.1 A). These fibrils were unilaterally injected into the striatum of 
the right brain hemisphere (Fig. 3.1 B). 
 
 
 
Fig. 3.1 Intrastriatal inoculation with α-synuclein fibrils. A) Negative stain electron microscopy image 
of aggregated mouse α-synuclein as oligomers and rod-shaped fibrils. Bar: 200 nm. B) Schematic view of 
the injection site. The striatum of the right brain hemisphere was targeted by the following stereotactic 
coordinates relative to the bregma: + 0.2 mm anterior-posterior, + 2.0 mm medial-lateral, + 2.6 mm dorso-
ventral (Franklin and Paxinos, 2008). 
 
 
During an observation time of 400 d, none of the inoculated animals showed any clinical 
symptoms of neurological disease. Histological analysis of the brains collected at 30, 90, 
180 and 400 days post inoculation (dpi) revealed that mice injected with α-synuclein 
fibrils developed mild pathology showing inclusions of phosphorylated α-synuclein only 
at 400 dpi and not at earlier time points (Table 2.1).  
 
 
 
Results 
34 
Table 2.1 Overview about intracerebrally injected Tg(Gfap-luc+/-) mice 
Mouse line Inoculum 
(amount) 
Inoculation 
route 
No. of mice with 
pathology/ 
no. of challenged 
mice  
 
Survival time 
[dpi] 
 
Tg(Gfap-luc+/-) 
mouse α-
synuclein fibrils 
(5µg) 
intracerebral 
8/ 8 
0/ 2 
0/ 3 
0/ 2 
400 
180 
90 
30 
Tg(Gfap-luc+/-) PBS intracerebral 
0/ 9 
0/ 3 
0/ 3 
0/ 2 
400 
180 
90 
30 
 
For the immunohistochemical analysis, brain sections were stained with two different α-
synuclein antibodies recognizing phosphorylation at serine 129. This phosphorylation site 
was previously described as the predominant post-translational modification of α-
synuclein in human synucleinopathy lesions (Anderson et al., 2006; Fujiwara et al., 
2002). Tissue sections probed with the 81A antibody indicated positive staining for 
phosphorylated and misfolded α-synuclein in cortical brain regions. Additional staining 
of tissue sections with the pSyn#64 antibody confirmed that α-synuclein pathology was 
restricted to the cortex (Fig. 3.2 A,B). The α-synuclein pathology was found throughout 
the entire cortex rostral and caudal from the injection site in both hemispheres, but not 
inside the striatum. The α-synuclein deposits showed a specific filamentous structure as 
characterized in humans as LNs and were distributed in the following interconnected 
regions: a) somatosensory cortex, b) insular cortices including the granular, dysgranular 
and agranular cortex and c) more caudal regions, including the ectorhinal, perirhinal and 
entorhinal cortices (Fig. 3.2 C). Surprisingly, and in contrast to brain sections from 
animals analyzed at 400 dpi, deposits of phosphorylated α-synuclein were not detectable 
at 30, 90 or 180 dpi (data not shown). 
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Fig. 3.2 Intrastriatal injection of recombinant mouse α-synuclein fibrils into Tg(Gfap-luc+/-) mice 
induced mild α-synuclein pathology in their brains. Immunohistochemical staining with A) the pSyn#64 
antibody or B) the 81A antibody detected filamentous aggregates of phosphorylated α-synuclein at 400 dpi. 
The pathology was restricted to the somatosensory cortex, insular cortices, and rhinal cortices as 
schematically shown in C) LNs are depicted by the red symbols. The distribution of pathology as detected 
with both antibodies was similar. The location of each coronal region is defined by its relative position to 
the bregma (Franklin and Paxinos, 2008). Bar = 20 μm. 
 
 
Results 
36 
Despite the presence of phosphorylated α-synuclein aggregates in the cortex at 400 dpi 
as detected by immunohistochemistry, high-molecular-weight species composed of 
sarcosyl-insoluble and phosphorylated α-synuclein extracted from whole brain 
homogenates could not be visualized by biochemical techniques (Fig. 3.3). The absence 
of insoluble α-synuclein oligomers was also evident at the earlier time points. 
 
 
 
Fig. 3.3 Detergent-insoluble species of phosphorylated α-synuclein were not detectable in the brains 
of Tg(Gfap-luc+/-) mice. Brain homogenates of mice intracerebrally injected with PBS or α-synuclein 
fibrils were analyzed at 400 dpi by immunoblotting. Probing with the EP1536Y antibody did not reveal the 
presence of oligomeric forms of phosphorylated α-synuclein. Equal sample loading was confirmed with an 
antibody against actin. Three animals were exemplary depicted for each treatment group. 
 
 
3.1.2 α-Synuclein fibrils intraglossally injected did not neuroinvade the 
brain 
To elucidate if α-synuclein fibrils injected into the tongue muscle show a similar 
propensity to seed pathology and neuroinvade the brain, Tg(Gfap-luc+/-) mice were 
intraglossally injected with recombinant α-synuclein fibrils or PBS into the lower bulk of 
the tongue muscle (Appendix Fig. 5.2 B). During the observation period of 400 d none of 
the animals showed obvious behavioral changes or signs of neurological disease (Table 
2.2). 
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Table 2.2 Overview about intraglossally injected Tg(Gfap-luc+/-) mice 
Mouse line 
Inoculum 
(amount) 
Inoculation 
route 
No. of mice with  
α-synuclein pathology/ 
no. of challenged mice 
Survival 
time 
[dpi] 
 
Tg(Gfap-luc+/-) 
mouse 
 α-synuclein 
fibrils (5µg) 
intraglossal 
0/ 8 
0/ 4 
0/ 2 
0/ 4 
400 
180 
90 
30 
Tg(Gfap-luc+/-) PBS intraglossal 
0/ 9 
0/ 2 
0/ 3 
0/ 5 
400 
180 
90 
30 
 
 
In addition, immunohistochemical analyses were performed in various brain areas that 
are interconnected to the cranial nerves to innervate the tongue. The stainings did not 
reveal deposits of phosphorylated α-synuclein when using both phosphorylation-specific 
antibodies pSyn#64 or 81A. The tongue is prevalently innervated by the bilaterally 
proceeding hypoglossal nerve originating at the hypoglossal nucleus. After none of the 
examined incubation periods, 30, 90, 180 or 400 dpi, misfolded and phosphorylated α-
synuclein was detectable in the hypoglossal nucleus. Exemplary, the hypoglossal nuclei 
at 30 and 400 dpi were depicted to demonstrate the lack of pathology in animals injected 
with α-synuclein fibrils or PBS (Fig. 3.4).  
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Fig. 3.4 Tg(Gfap-luc+/-) mice intraglossally injected with α-synuclein fibrils did not reveal any α-
synuclein pathology in their hypoglossal nuclei. For the immunohistochemical analysis brain sections 
were stained with the pSyn#64 antibody that recognizes phosphorylated α-synuclein. None of the fibril- or 
PBS-injected animals showed deposits of phosphorylated α-synuclein in their hypoglossal nuclei. Shown 
here are only results for brains collected at 30 (A) and 400 dpi (B). Bar = 200 μm.  
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Moreover, biochemical analysis by immunoblotting revealed that the sarcosyl-insoluble 
fractions of the animal brains intraglossally injected with α-synuclein seeds or PBS did 
not contain any high-molecular weight species of phosphorylated α-synuclein. The lack 
of phosphorylated aggregates was obvious at all examined time points as exemplary 
shown at 30 dpi (Fig. 3.5).  
 
 
 
 
Fig. 3.5 Intraglossally injected Tg(Gfap-luc+/-) mice did not show any insoluble and phosphorylated 
α-synuclein aggregates in their brains. For biochemical analysis sarcosyl-insoluble fractions were 
extracted at 30 dpi from the brains of mice intraglossally injected with α-synuclein fibrils or PBS. Detection 
with the EP1536Y antibody revealed only a weak signal for the monomeric form of phosphorylated α-
synuclein with approximately 14 kDa. Equal protein loading was confirmed with an antibody against actin. 
Samples from three different animals are shown for each treatment group. 
 
 
To investigate whether the injected fibrils may have seeded disease-associated deposits 
around the injection site, the tongues of the injected mice were immunohistochemically 
analyzed with the pSyn#64 antibody. The analysis did not reveal the presence of 
phosphorylated α-synuclein in any of the analyzed tongues, including those collected at 
30 dpi (Fig. 3.6). In particular, the epithelial layers, the skeletal muscles, the surrounding 
epithelium of blood vessels, and the nerve bundles remained free of misfolded α-
synuclein. Equally, biochemical analysis by immunoblotting with the EP1536Y antibody 
did not detect sarcosyl-insoluble phosphorylated α-synuclein extracted from whole 
tongue homogenates at all examined time points. 
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Fig. 3.6 Tg(Gfap-luc+/-) mice intraglossally injected with α-synuclein fibrils did not accumulate 
phosphorylated α-synuclein in their tongues. Tongues of mice intraglossally injected were 
immunohistochemically analyzed at 30 dpi with the phosphorylation specific pSyn#64 antibody. None of 
the α-synuclein- (SYN) or PBS-injected animals showed deposits of phosphorylated α-synuclein in their 
tongues as illustrated for the epithelium (E), the lamina propria (LP), the skeletal muscles (SM), the fibers 
of nerve bundles (NB) and the surrounding tissue of blood vessels (BV). Bar = 100 μm. 
 
 
3.1.3 Inoculated mice did not display motor deficits  
To uncover abnormalities in motor behavior and performance caused by neuronal failure, 
the behavior of intracerebrally (Fig. 3.7 A,B) or intraglossally (Fig. 3.7 C,D) injected 
Tg(Gfap-luc+/-) mice was analyzed. Therefore, animals were tested in the rotarod-
performance (Fig. 3.7 A,C) and the wire-hang test (Fig. 3.7 B,D). The rotarod-
performance test provides information regarding an animal’s ability to maintain balance 
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and coordination. The wire-hang assay measures an animal’s grip strength. Both tests 
demonstrated that fibril-injected animals did not diminish performance when compared 
to PBS-injected control mice. However, an age-dependent reduction in performance 
became apparent at least at 360 dpi in both assays independent of the inoculum or the 
injection route (Fig. 3.7).  
 
 
 
 
Fig. 3.7 Intracerebrally and intraglossally inoculated Tg(Gfap-luc+/-) mice did not show behavioral 
deficits. Neither the rotarod-performance test (A and C) nor the wire-hang test (B and D) revealed any 
significant differences between animals injected intracerebrally (A and B) with α-synuclein fibrils (light 
red) or PBS (dark red). Similarly, animals intraglossally injected (C and D) with α-synuclein fibrils (light 
blue) or PBS (dark blue) did not show any behavioral deficits for both tests. At least eight animals were 
tested for each treatment group in the rotarod-performance test at 30, 90, 180, 270, and 360 dpi. In the wire-
hang-test at least five animals were tested at 90, 180, 270, and 360 dpi. Error bars indicate SEM. * P < 0.05 
(paired t-test). 
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3.1.4 Injected mice did not develop persistent CNS inflammation  
Since Tg(Gfap-luc+/-) mice express luciferase from the GFAP (Glial fibrillary acidic 
protein) promoter the activity of astrocytes can be easily monitored by bioluminescence 
imaging (BLI) as previously shown in these mice after infection with prions (Tamgüney 
et al., 2009a). To assess whether injection of α-synuclein fibrils or PBS in Tg(Gfap-luc+/-
) reporter mice causes sustained neuroinflammation, the activity of astrocytes was 
monitored by BLI throughout the entire experimental time course. Tg(Gfap-luc+/-) mice 
were intracerebrally injected with RML prions as a positive or with PBS as a negative 
control. Prion-infected animals began to show an increased radiance ~10 weeks before 
they finally developed neurological signs of prion disease and had to be sacrified (Fig. 
3.8A). Approximately eight weeks after prion injection, animals emitted from their brains 
bioluminescence (BL) levels above a threshold of 1.5 million photons/s/cm2/sr. In this 
setting, this value was indicative for astrocytic activation. In contrast, PBS-injected 
negative control animals did not show an increase in BL throughout the entire 19 weeks 
of the experiment. An initial increase exceeding 1.5 million photons/s/cm2/sr in prion- 
and PBS-injected mice at 2 weeks post inoculation was caused by the inoculation-induced 
trauma resulting in transient astrogliosis. For Tg(Gfap-luc+/-) mice that were either 
intracerebrally or intraglossally injected with α-synuclein fibrils or PBS, BLI did not 
reveal an increase in BL throughout the observation course of 54 weeks (Fig. 3.8 B,C). 
In comparison to the intraglossal injections, injections into the cerebrum, transiently led 
to elevated BL as a result of surgery-induced inflammation.  
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Fig. 3.8 Intracerebral and intraglossal challenge with α-synuclein prionoids did not cause astrocytic 
gliosis in Tg(Gfap-luc+/-) mice. The activation of astrocytes in the brains of intracerebrally or intraglossally 
injected Tg(Gfap-luc+/-) mice was measured by BLI every first to second week. A) Mice intracerebrally 
injected with RML prions displayed elevated BL signals exceeding a threshold of 1.5x106 photons/s/cm2/sr 
(indicated as blue-dotted line) at 8 weeks post inoculation (black circles). Intracerebral injection with PBS 
did not induce astrocytic activation (grey squares). B) BL measured from the brains of animals 
intracerebrally injected with α-synuclein fibrils (red squares) or PBS (blue circles) remained predominantly 
under the threshold of 1.5 x106 photons/s/cm2/sr. C) BL did not significantly increase when animals were 
intraglossally injected with α-synuclein fibrils (red squares) or PBS (blue circles). Images are representative 
of animals that were quantified for BLI at the latest time point. At least 13 animals were used for BLI at 
each time point for all conditions. Error bars indicate SEM. 
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Since the cortex of intracerebrally injected animals exclusively accumulated 
phosphorylated α-synuclein, it might be the most probable brain region, beside the 
injection site, to develop signs of neuroinflammation. Immunohistochemical staining 
with an antibody against GFAP did not show any signs of astrocytic gliosis in the striatum 
and cortical regions of Tg(Gfap-luc+/-) mice injected with α-synuclein fibrils or PBS (Fig. 
3.9 A). The injection did not lead astrocytes to change their morphology or to proliferate. 
Furthermore, to analyze whether these animals had reactive microgliosis, brain sections 
were additionally stained with an antibody to ionized calcium-binding adapter molecule 
1 (IBA-1). IBA-1 is a marker for activated microglia that is also known as AIF-1 (allograft 
inflammatory factor 1). Animals sacrified at 400 dpi did not reveal signs for reactive 
microgliosis showing comparable number of cells with unchanged morphology between 
all treatment groups (Fig. 3.9 B).   
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Fig. 3.9 Intracerebral injections of α-synuclein fibrils in Tg(Gfap-luc+/-) mice did not cause 
neuroinflammation. A) Immunohistochemical analysis did not reveal differences between PBS- and α-
synuclein injected animals after staining brain sections of animals sacrified at 400 dpi with an antibody to 
GFAP. Animals in both treatment groups did not display any signs for astrocytic gliosis. B) Staining with 
an IBA-1 antibody equally confirmed the absence of microgliosis in both treatment groups at 400 dpi. 
Representatively, stained sections of the striatum and the insular cortex are shown. Bar = 100 μm. 
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3.2 Susceptibility of Tg(M83+/-:Gfap-luc+/-) mice to 
peripherally injected α-synuclein fibrils  
3.2.1 Injection of α-synuclein fibrils induced neuropathology and 
neurologic disease  
To investigate whether animals overexpressing the A53T mutant of human α-synuclein 
would develop α-synuclein pathology after peripheral challenge, bigenic, hemizygous 
Tg(M83+/-:Gfap-luc+/-) reporter mice were peripherally injected with misfolded α-
synuclein. As also previously reported, the Tg(M83+/-:Gfap-luc+/-) mice did not develop 
any spontaneous neurological disease or neuropathology for at least 22 months of age 
(Watts et al., 2013). For the peripheral challenge, Tg(M83+/-:Gfap-luc+/-) mice were 
injected with human α-synuclein fibrils into the tongue or peritoneal cavity (Appendix 
5.2 C). The inoculum contained clusters of rod-shaped fibrils of different length (Fig. 3.10 
A).  
 
 
 
Fig. 3.10 Intraperitoneal or intraglossal challenge with α-synuclein fibrils caused disease in Tg(M83+/-
:Gfap-luc+/-) mice. A) The electron microscopy image shows recombinant wild-type human α-synuclein as 
clusters of rod-shaped aggregates of different length. Bar = 100 nm. B) The Kaplan-Meier survival curves 
indicate that 4 mice of 5 intraperitoneally injected with α-synuclein fibrils developed neurological 
dysfunction and disease in 229 ± 17 days (mean ± SD; red filled squares), whereas none of the PBS-injected 
control mice (n = 5) developed signs of neurological illness within 420 dpi (red framed squares). Among 
the intraglossally injected animals only one of five died after 285 dpi (blue filled circles), whereas the 
residual four animals as well as the PBS-injected mice (n = 5) (blue framed circles) did not show any signs 
of disease.  
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Intraglossal injection of Tg(M83+/-:Gfap-luc+/-) mice with recombinant human α-
synuclein fibrils caused neurologic disease in only one mouse of five, which died after 
285 d as presented in the Kaplan-Meyer survival curve (Fig. 3.10 B, Table 2.3). All other 
mice, including those intraglossally injected with PBS did not develop neurologic disease 
during 420 d of observation. The intraperitoneal challenge of Tg(M83+/-:Gfap-luc+/-) mice 
with recombinant human α-synuclein fibrils induced clinical symptoms of neurologic 
disease in four of five animals with marked signs of paralysis of the hindlimb muscles, 
kyphosis, tail rigidity, and reduced activity within 229 ± 17 d (mean ± SD) (Fig. 3.11). 
Whereas Tg(M83+/-:Gfap-luc+/-) mice injected with PBS remained healthy throughout the 
observation period of 420 days (Fig. 3.10 B, Table 2.3) (Breid et al., 2016). 
 
Table 2.3 Overview about peripherally injected Tg(M83+/-:Gfap-luc+/-) mice 
Mouse line 
Inoculum 
(amount) 
Inoculation 
route 
No. of sick mice/ 
no. of challenged 
mice 
Mean survival time 
± SD [dpi]/ 
harvesting 
Tg(M83+/-:Gfap-luc+/-) 
human α-
synuclein fibrils 
(50µg) 
intraperitoneal 4/ 5 229 ± 17 
Tg(M83+/-:Gfap-luc+/-) PBS intraperitoneal 0/ 5 420 
Tg(M83+/-:Gfap-luc+/-) 
human α-
synuclein fibrils 
(10µg) 
intraglossal 1/ 4 285/ 420 
Tg(M83+/-:Gfap-luc+/-) PBS intraglossal 0/ 5 420 
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Fig. 3.11 Diseased Tg(M83+/-:Gfap-luc+/-) mouse after intraperitoneal injection with α-synuclein 
fibrils. The mouse intraperitoneally inoculated with α-synuclein fibrils developed severe neurological 
symptoms with paralysis of the hindlimbs, kyphosis, tail rigidity, and reduced activity at 215 dpi. 
 
 
3.2.2 Intraglossally injected mice developed neurologic disease 
Intraglossally injected Tg(M83+/-:Gfap-luc+/-) mice were weighed weekly and continued 
to gain weight, except for animal 121 that had been injected with fibrils and started to 
lose weight eight weeks before it became terminally sick and died (Fig. 3.12 A,B). 
Biochemical analysis revealed that the diseased animal had accumulated aggregated 
species of phosphorylated α-synuclein in its CNS; in both the brain and spinal cord 
sarcosyl-insoluble fractions of oligomeric α-synuclein species were detectable by the 
phosphorylation specific antibody EP1536Y (Fig. 3.12 C). A pronounced signal was 
achieved for an oligomeric form below 38 kDa. The equal protein loading was shown by 
probing the immunoblot with an actin antibody. The non-diseased, healthy animals did 
not accumulate aggregated and phosphorylated α-synuclein species in their brains or 
spinal cords, equally to the PBS-inoculated controls. The endogenous monomeric α-
synuclein in the brain samples was detectable to a similar extend in the healthy and 
diseased animals. In contrast, the endogenous, monomeric and phosphorylated α-
synuclein in the spinal cord samples was less abundant in the non-diseased animals than 
in the affected mouse 121 (Fig. 3.12 C) (Breid et al., 2016). 
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Fig. 3.12 The intraglossally injected and diseased Tg(M83+/-:Gfap-luc+/-) animal lost its bodyweight 
and accumulated phosphorylated α-synuclein in its CNS. A) Animal 121 began to lose weight at least 
8 weeks before it died after intraglossal injection of α-synuclein fibrils (black squares). In contrast, the other 
animals intraglossally injected with α-synuclein fibrils remained healthy throughout the 420 d period of the 
experiment and continuously gained weight (grey shaded symbols), B) as did all PBS-injected animals. In 
panels A) and B) female mice are respresented by circles and male mice by squares. C) For biochemical 
analysis the brain and spinal cord tissues were harvested once animals showed clinical symptoms or finally 
at 420 dpi. The diseased animal 121 had accumulated sarcosyl-insoluble aggregates of phosphorylated α-
synuclein in its brain and spinal cord, which were detected with the EP1536Y antibody recognizing 
phosphorylated α-synuclein. In contrast, mice that did not develop disease after intraglossal injection 
showed only the monomeric form of phosphorylated α-synuclein in their brain and spinal cord extracts. 
The molecular weight is shown in kilodalton. Equal sample loading in each lane was confirmed by detection 
of actin. 
 
 
 
 
 
Results 
50 
Surprisingly, none of the animals intraglossally injected with α-synuclein fibrils revealed 
any accumulations of phosphorylated α-synuclein in their brains or spinal cords, when 
they were analyzed by immunohistochemistry. Brains and spinal cords were collected at 
420 dpi and the tissue sections were probed with an antibody detecting phosphorylation 
at serine 129 of α-synuclein (pSyn#64). Analysis was performed for the entire brain and 
spinal cord including the cortex, striatum, hippocampus, amygdala and hypoglossal 
nucleus as well as cervical, thoracic and lumbar parts of the spinal cord (data not shown). 
Even the hypoglossal nucleus in the brainstem that is directly connected to the tongue by 
the bilateral hypoglossal nerve did not display any aggregates of phosphorylated α-
synuclein, which is a likely route for neuroinvasion as it has been shown for prions after 
intraglossal inoculation (Bartz et al., 2003) (Fig. 3.13).  
 
 
 
Fig. 3.13 The hypoglossal nuclei of Tg(M83+/-:Gfap-luc+/-) mice injected with α-synuclein fibrils did 
not contain detectable deposits of disease-associated α-synuclein. For immunohistochemical analysis 
the brains of intraglossally injected animals at 420 dpi were stained with the phosphorylation-specific 
pSyn#64 antibody. None of the animals injected with α-synuclein fibrils (n=5) or PBS (n=5) displayed 
deposits of phosphorylated α-synuclein. Bar = 400 μm. 
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To analyze whether α-synuclein prionoids injected into the tongue muscle seeded 
aggregation of phosphorylated α-synuclein out of the injection site, tongues were 
dissected at 420 dpi and stained with the phosphorylation specific antibody pSyn#64. 
Animals injected with α-synuclein fibrils or PBS did not accumulate any deposits of 
phosphorylated α-synuclein throughout the entire tongue muscle. All types of tissues 
including the epithelial layers, the skeletal muscles, the surrounding epithelium of blood 
vessels, and the nerve bundles were free of pathology (Fig. 3.14). 
 
 
 
Fig. 3.14 Tg(M83+/-:Gfap-luc+/-) mice intraglossally injected with α-synuclein fibrils did not show any 
signs of α-synuclein pathology in their tongues. For the immunohistochemical analysis the tongues of 
mice intraglossally injected with α-synuclein fibrils or PBS were collected at 420 dpi and stained with the 
phosphorylation-specific pSyn#64 antibody. None of the injected animals had accumulated any 
phosphorylated deposits of α-synuclein in the tongue as illustrated for the epithelium (E), lamina propria 
(LP), skeletal muscles (SM), fibers of nerve bundles (NB) or surrounding tissue of blood vessels (BV). Bar 
= 100 μm 
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3.2.3 Severe neurologic illness in intraperitoneally injected mice   
Further characterization of the intraperitoneally injected Tg(M83+/-:Gfap-luc+/-) mice 
revealed that in comparison to PBS-injected healthy controls, fibril-injected animals 
strikingly lost bodyweight beginning six-to-eight weeks before they developed signs of 
neurologic disease (Fig. 3.15 A,B). In contrast, animals that did not develop disease, 
continuously gained weight over the entire 420 d observation period. To detect disease-
associated α-synuclein species, sarcosyl-insoluble protein fractions from brains and 
spinal cords of all mice were biochemically analyzed. Similar to the animal (mouse 121) 
diseased after intraglossal injection, the intraperitoneally injected and diseased mice also 
accumulated sarcosyl-insoluble aggregates of phosphorylated α-synuclein in their brains 
and spinal cords (Fig. 3.15 C).. By probing the immunoblots with the phosphorylation 
specific antibody EP1536Y, aggregated and phosphorylated species of α-synuclein were 
detected as additional bands above the molecular weight of monomeric α-synuclein with 
14 kDa. 
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Fig. 3.15 Intraperitoneally with α-synuclein fibrils injected and diseased Tg(M83+/-:Gfap-luc+/-) mice 
showed a severe loss of weight and accumulated phosphorylated α-synuclein in their CNS. A) Animals 
that received an intraperitoneal injection of α-synuclein fibrils and developed neurological illness first 
began to lose weight 6-8 weeks before they developed signs of neurologic disease (black circles). The one 
animal that did not get sick gained weight throughout the entire observation period as also shown for B) 
PBS-injected animals (grey shaded symbols). Circles represent female mice and squares represent male 
mice. C) Sick fibril-injected mice had accumulated high-molecular weight species of sarcosyl-insoluble 
phosphorylated α-synuclein in their brains and spinal cords when probed with the EP1536Y antibody. PBS 
injected control animals exhibited monomeric α-synuclein only in extracts from their brains, but not spinal 
cord. Molecular weight is shown in kilodalton. Equal sample loading in each lane was verified by detection 
of actin. 
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3.2.3.1 Distribution of neuropathology in the brains and spinal cords of 
diseased mice 
To define the neuroanatomical distribution of neuropathological lesions in brains and 
spinal cords of diseased Tg(M83+/-:Gfap-luc+/-) mice, immunohistochemical staining with 
two different antibodies against phosphorylated α-synuclein, pSyn#64 and pSyn81A were 
performed. In the brains of the diseased animals abundant deposits of phosphorylated α-
synuclein were found in neuronal cell bodies or their processes, whereas the brains of 
PBS-injected control mice were free of pathology (Fig. 3.16). Both the antibodies 
marking phosphorylated α-synuclein revealed a similar distribution pattern of pathology. 
In diseased animals deposits of phosphorylated α-synuclein were widespread throughout 
the cerebrum but absent in the cerebellum and the rostral lying areas of the olfactory bulb. 
The highest abundance of neuronal inclusions was detected in the hypothalamus, 
amygdala and brainstem as summarized in the pathology distribution map (Fig. 3.17). 
Equally, the fibril-injected animal, that did not develop neurologic disease until 420 dpi, 
was free of pathological deposits in its brain (data not shown).  
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Fig. 3.16 Tg(M83+/-:Gfap-luc+/-) mice developed severe neuropathology in their brains after 
intraperitoneal injection with α-synuclein prionoids. A) Once the animals developed clinical signs of 
disease or at 420 dpi their brains were analyzed immunohistochemically. Brain sections were 
immunostained with the (A) pSyn#64 and (B) 81A antibody recognizing phosphorylation at serine 129 of 
α-synuclein. Diseased animals accumulated abundant deposits of phosphorylated α-synuclein throughout 
their brains including the motor cortex, striatum, corpus callosum, hypothalamus, amygdala, and brain stem 
with the hypoglossal and dorsal motor nuclei. The olfactory bulb was free of α-synuclein pathology. 
Deposits of phosphorylated α-synuclein were abundant in neuronal cell bodies and their neurites. The PBS-
injected mice did not display any CNS pathology. Bar = 50 μm. 
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Fig. 3.17 Distribution of misfolded and phosphorylated α-synuclein in the brains of diseased 
Tg(M83+/-:Gfap-luc+/-) mice. The schematic view depicts the distribution of α-synuclein deposits as 
detected by two antibodies, pSyn#64 and pSyn81A. Abundant deposits of phosphorylated α-synuclein were 
found throughout the cerebrum except the olfactory bulb and the cerebellum that remained free of 
pathology. Deposits of phosphorylated α-synuclein were present within neuronal cell bodies (red circles) 
and neurites (red rods). The position of each coronal brain section is stated relative to the bregma (Franklin 
and Paxinos, 2008). 
 
 
Immunostaining of spinal cord sections revealed that neuronal deposits of phosphorylated 
α-synuclein were widely and consistently distributed in the gray matter of its cervical, 
thoracic and lumbar segments (Fig. 3.18 A,B). The use of antibodies that are specific for 
mouse or human α-synuclein (Appendix 5.1) showed that deposits of aggregated α-
synuclein in the CNS of diseased animals did not only consist of transgenically expressed 
mutant human α-synuclein as detected with the Syn 211 antibody, but also of 
endogenously expressed mouse α-synuclein as detected with the D37A6 antibody. In 
contrast, α-synuclein deposits were not found in the spinal cord of PBS-injected control 
mice (Fig. 3.18 A).  
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Fig. 3.18 The Tg(M83+/-:Gfap-luc+/-) mice developed neurophathology in their spinal cords after 
intraperitoneal injection with α-synuclein fibrils. A) Immunohistochemical staining of spinal cord 
sections with the pSyn64# antibody displayed abundance of phosphorylated α-synuclein within the gray 
matter. The antibodies Syn211 and D37A6 specifically recognize human or mouse α-synuclein and 
revealed that both proteins were abundant in deposits within the gray matter. Bar = 50 μm. B) The schematic 
coronal view through the spinal cord depicts that α-synuclein deposits were restricted to the gray matter. 
Phosphorylated α-synuclein deposits were located in cell bodies (red circle) and within neurites (red rods). 
A similar pathology distribution was observed throughout the entire spinal cord including cervical, thoracic 
and lumbar segments.  
 
 
To specify which type of neuron in the spinal cord was affected by deposition of α-
synuclein, additional immunofluorescence analyses for cholinergic motor neurons that 
innervate extrafusal muscle fibers, and phosphorylated α-synuclein were performed. Co-
staining with antibodies to phosphorylated α-synuclein and cholinergic acetyltransferase 
(ChAT) revealed that deposits of misfolded α-synuclein clearly localized to cholinergic 
motor neurons in the ventral horn of diseased animals. Whereas, α-synuclein pathology 
was not detectable in PBS-injected control mice (Fig. 3.19). 
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Fig. 3.19 Deposits of phosphorylated α-synuclein were present in motorneurons of diseased Tg(M83+/-
:Gfap-luc+/-) mice. Immunofluorescence analysis with the pSyn64# antibody against phosphorylated α-
synuclein and an antibody against choline acetyltransferase (ChAT) revealed deposits of phosphorylated α-
synuclein within cholinergic neurons in the spinal cord of diseased animals. Healthy control animals were 
free of pathology. Nuclear staining with DAPI is shown in blue. Bar = 20 μm.   
 
 
3.2.3.2 Deposits of phosphorylated α-synuclein colocalized with 
ubiquitin and p62 
For further characterization of α-synuclein positive deposits in the CNS of diseased mice, 
brain and spinal cord sections were immunofluorescently labeled with antibodies against 
phosphorylated α-synuclein and ubiquitin. Phosphorylated α-synuclein was found to 
colocalize with ubiquitin in the brains and spinal cords of diseased animals indicating a 
dysregulated protein degradation and homeostasis (Fig. 3.20 A,B). Similarly, 
phosphorylated α-synuclein also colocalized with the ubiquitin-binding protein p62 
(sequestosme-1) in brain and spinal cord sections of diseased animals (Fig. 3.20 C,D). In 
contrast, stained brain and spinal cord sections of PBS-injected healthy control mice did 
not reveal aggregates or colocalization for any of these proteins (Fig. 3.20 A-D).  
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Fig. 3.20 Colocalization of misfolded and phosphorylated α-synuclein with ubiquitin and p62 in 
diseased Tg(M83+/-:Gfap-luc+/-) mice. Immunofluorescence staining for phosphorylated α-synuclein with 
the EP1536Y antibody and an antibody against ubiquitin revealed colocalization of both proteins in deposits 
in the (A) brain and (B) spinal cord of diseased mice. In contrast, the brain and spinal cord of PBS-injected 
animals did not display any deposits or colocalization of these proteins as shown in a merged view. In 
addition, when (C) brain and (D) spinal cord sections were stained for phosphorylated α-synuclein with the 
pSyn64# antibody and an antibody against p62 (sequestosme-1) an unambiguous colocalization was 
detectable. PBS-injected control animals did not show aggregation or colocalization for any of these 
proteins in brain or spinal cord, as indicated in the merged image. Nuclear staining with DAPI is shown in 
blue. Bar = 20 μm. 
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3.2.3.3 Phosphorylated α-synuclein colocalized with dopaminergic 
neurons in the substantia nigra 
Since loss or dysfunction of dopaminergic neurons may be causative for an impaired 
locomotor activity (Masliah et al., 2000), it was examined whether deposits of 
phosphorylated α-synuclein are formed in dopaminergic neurons within the substantia 
nigra of diseased mice. Therefore, co-immunofluorescence stainings with antibodies 
detecting tyrosine hydroxylase (TH) that is expressed in dopaminergic neurons and 
phosphorylated α-synuclein were perfomed. The deposits of phosphorylated α-synuclein 
clearly colocalized with TH-positive neurons of the substantia nigra (Fig. 3.21).   
 
 
 
Fig. 3.21 Diseased Tg(M83+/-:Gfap-luc+/-) mice accumulated α-synuclein deposits in their substantia 
nigra. Immunofluorescence staining with the pSyn#64 antibody against phosphorylated α-synuclein and 
an antibody against tyrosine hydroxylase (TH) showed clear localization of phosphorylated α-synuclein 
deposits in dopaminergic neurons. Nuclear staining with DAPI is shown in blue. Bar = 50 μm.   
 
 
3.2.4 Reactive astrogliosis and microgliosis in diseased animals 
Because neurodegenerative diseases are often associated with neuroinflammation 
characterized by activated microglia and astrocytes, the brains of intraperitoneally and 
intraglossally injected Tg(M83+/-:Gfap-luc+/-) mice were monitored for these 
neuroinflammatory markers. Immunofluorescence staining with an antibody to GFAP 
visualizes astrocytes and an antibody to phosphorylated α-synuclein revealed reactive 
astrocytic gliosis in regions with phosphorylated α-synuclein deposits (Fig. 3.22 A). 
Abundance of activated astrocytes was found in the brainstem as shown here for the 
gigantocellular reticular nucleus. In contrast, stained tissue sections of healthy PBS-
injected control mice did not present any α-synuclein deposits or activated astrocytes. 
Furthermore, to determine if microglia are also activated, the brain sections were stained 
for IBA-1. The sections derived from the brainstem of diseased Tg(M83+/-:Gfap-luc+/-) 
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mice showed abundant activated microglia in the presence of deposits of phosphorylated 
α-synuclein. Whereas in the brains of PBS-injected control mice, IBA-1 positive cells 
were less abundant and still showed a more ramified morphology indicative of an absence 
of microgliosis (Fig. 3.22 A).  
 
As a second non-invasive measure to monitor astrocytic gliosis, BL emitted from the 
brains of injected Tg(M83+/-:Gfap-luc+/-) reporter mice was regularly measured 
throughout the course of the experiment. The intraperitoneally with α-synuclein fibrils 
injected and diseased mice displayed increased radiance (>2 x 106 photons/s/cm2/sr) 
emitted from their brains shortly before they developed signs of neurologic disease with 
a mean incubation time of 229 ± 17 days (Fig. 3.22 B). As shown in the left photograph, 
intraperitoneal injection with α-synuclein fibrils not only induced an increase in BL in the 
brain but also in the spinal cord of diseased animals (Fig. 3.22 C, left image). Animals 
that did not develop disease did not show BL above the threshold of 2 x 106 
photons/s/cm2/sr. Elevated BL indicative for reactive astrogliosis was also measured for 
animal 121 two weeks before it died at 285 dpi after intraglossal injection with α-
synuclein prionoids (Fig. 3.22 B,C, center image). Thus, aggregation of phosphorylated 
α-synuclein in diseased Tg(M83+/-:Gfap-luc+/-) mice was accompanied by 
neuroinflammation consisting of reactive gliosis and microgliosis.  
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Fig. 3.22 Fibril-injected Tg(M83+/-:Gfap-luc+/-) mice developed neuroinflammation shortly before 
signs of neurologic illness appeared. A) Immunofluorescence staining with an antibody against GFAP 
and an antibody to phosphorylated α-synuclein revealed that diseased mice had accumulated reactive 
astrocytes in regions with deposits of α-synuclein. Healthy animals did not show signs of astrogliosis. 
Staining with an antibody to the microglial marker IBA-1 and an antibody for phosphorylated α-synuclein 
displayed microgliosis near deposits of phosphorylated α-synuclein. In healthy animals deposits of α-
synuclein and IBA-1 positive cells were less abundant. Bar = 20 μm. B) After intraperitoneal challenge of 
Tg(M83+/-:Gfap-luc+/-) mice with α-synuclein fibrils, elevated levels of BL with >2 x 106 photons/s/cm2/sr 
were measured from the brains of four mice (blue, green, brown, and orange circles) a few weeks before 
they developed neurologic symptoms. One animal never showed elevated BL and did not develop disease 
(red circles). One of five mice intraglossally injected with α-synuclein fibrils showed increased BL levels 
shortly before it died (magenta circles). PBS-injected control animals never exhibited elevated BL that 
exceed the threshold of 2 x 106 photons/s/cm2/sr (black circles). Error bars show SD (n=4). C) 
Intraperitoneally fibril-injected Tg(M83+/-:Gfap-luc+/-) mice emitted elevated BL from their brains and 
spinal cords. After intraglossal injection with α-synuclein fibrils, only animal 121 developed signs of 
reactive gliosis. Control animals injected with PBS did not emit elevated BL from their brains.  
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3.3 Aerosols made of MSA brain homogenate did not induce 
neuropathology 
To elucidate whether disease-associated species of α-synuclein have the propensity to 
pass the olfactory epithelium and to induce neurodegeneration similar to prions, 
Tg(M83+/-:Gfap-luc+/-) reporter mice were nasally exposed to aerosolized α-synuclein 
particles originating from MSA brain homogenate (Appendix Fig. 5.1 D). Biochemical 
analysis of the MSA brain homogenate revealed that it contained detergent-insoluble, 
phosphorylated α-synuclein species of high-molecular weight exceeding that of 
monomeric α-synuclein (Fig. 3.23). 
 
 
 
Fig. 3.23 MSA brain homogenate with detergent-insoluble α-synuclein species. Sarcosyl or Triton X-
100 insoluble protein fractions were extracted from the MSA brain homogenate and analyzed by probing 
the immunoblot with the EP1536Y antibody. Both extraction protocols revealed the presence of monomeric 
and oligomeric species of phosphorylated α-synuclein in the MSA brain homogenate. Molecular weight is 
shown in kilodalton. 
 
 
The infection dynamics of Tg(M83+/-:Gfap-luc+/-) mice nasally exposed to aerosols made 
from 1 %, 5 %, 10 %, 20 % (w/v) MSA brain homogenate in PBS and the control group 
are shown in Table 2.4. 
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Table 2.4 Aerosol transmission experiments in Tg(M83+/-:Gfap-luc+/-) mice 
Mouse line Inoculum 
(amount) 
Inoculation 
route 
No. of sick mice/ 
no. of challenged 
mice 
Survival time 
[dpi] 
 
Tg(M83+/-:Gfap-luc+/-) PBS inhalation 0/ 5 600 
Tg(M83+/-:Gfap-luc+/-) 
1 % MSA brain 
homogenate 
inhalation 0/ 5 600 
Tg(M83+/-:Gfap-luc+/-) 
5 % MSA brain 
homogenate 
inhalation 0/ 5 600 
Tg(M83+/-:Gfap-luc+/-) 
10 % MSA brain 
homogenate 
inhalation 0/ 10 600 
Tg(M83+/-:Gfap-luc+/-) 
20 % MSA brain 
homogenate 
inhalation 0/ 5 600 
 
 
Animals were monitored for up to 600 dpi without developing any signs of neurologic 
illness. Throughout the entire experimental course all animals were also assessed for 
neuroinflammatory changes by measuring the BL emitted from their brains. Neither 
animals exposed to MSA nor to PBS showed notable changes in BL during the 
observation course of 600 d. Thus, indicating that these animals did not develop any signs 
of astrocytic gliosis following exposure to aerosols (Fig. 3.24).   
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Fig. 3.24 Tg(M83+/-:Gfap-luc+/-) challenged with aerosols of MSA brain homogenate did not show 
signs of astrocytic glisis. BL measured from the brains of Tg(M83+/-:Gfap-luc+/-) reporter animals exposed 
to aerosolized brain homogenates of 20 % (yellow circles), 10 % (red circles), 5 % (green circles), and 1 % 
(pink circles) was not elevated when compared to control animals (PBS, blue circles). The radiance was 
measured in photons/s/cm2/sr. Error bars show SEM [20 % MSA: n=5; 10 % MSA: n=10; 5 % MSA: n=5; 
1 % MSA: n=5; PBS: n=5].  
 
 
Immunohistochemical analysis of brains and spinal cords of all treatment groups (PBS, 1 
% MSA, 5 % MSA, 10 % MSA, and 20 % MSA) harvested at 600 dpi did not reveal 
accumulation of disease-associated α-synuclein species. Staining for phosphorylated α-
synuclein with the pSyn#64 antibody was negative throughout the entire cerebrum, 
including the striatum, amygdala, hippocampus, and brain stem. In particular, the 
olfactory bulb, which is directly connected to the olfactory epithelium, was free of 
pathology (Fig. 3.25). 
 
 
 
Fig. 3.25 Exposure of Tg(M83+/-:Gfap-luc+/-) mice to aerosols containing pathological α-synuclein did 
not induce neuropathology in the olfactory bulb. Immunohistochemical analysis with the pSyn64# 
antibody of brains of animals exposed with 20 % MSA brain homogenate did not show any deposition of 
phosphorylated α-synuclein at 600 dpi. AO: anterior olfactory area, GrO: granule cell layer, IPI: internal 
plexifrom layer, Mi: mitral cell layer, EPI: external plexiform layer. Bar = 100 μm.   
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4 Discussion 
4.1 Virulence of α-synuclein prionoids inoculated into Tg(Gfap-
luc+/-) mice 
4.1.1 Intracerebral injection of α-synuclein prionoids induced mild α-
synuclein pathology  
It has been previously shown that an intracerebral injection either with recombinant α-
synuclein or patient derived pathogenic α-synuclein species causes prion-like spreading 
and formation of α-synuclein deposits in the CNS of wild-type mice (Luk et al., 2012a; 
Masuda-Suzukake et al., 2013; Recasens et al., 2014; Sacino et al., 2013a). Luk et al. 
(2012a) observed phosphorylated α-synuclein in inclusions to a high extend already at 30 
dpi. They reported a time-dependent spreading of α-synuclein inclusions from the 
striatum to more distal interconnected brain regions such as the amygdala and the 
olfactory bulb in both hemispheres. In this work intrastriatal injection of mouse α-
synuclein fibrils only caused a mild neuropathology in the cortex of Tg(Gfap-luc+/-) mice 
after a long incubation time of 400 d (3.1.1). Injection of α-synuclein fibrils into the 
striatum did not result in deposition of phosphorylated α-synuclein around the injection 
site at none of the examined time points for up to 400 d. Opposite to previous findings 
(Luk et al., 2012a) and probably due to the mild α-synuclein pathology, the animals 
inoculated in this study did not display any behavioral deficits in the wire hang or rotarod-
performance test. Thus, their motor neurons innervating skeletal muscles remained 
unaffected.  
 
Considering that the genetic background of Tg(Gfap-luc+/-) mice is essentially wild-type 
as far as α-synuclein is concerned, these mice are comparable to the non-transgenic 
animals used in previous studies. However, the degree of neuropathology and its spatio-
temporal spreading greatly differs between individual studies (Masuda-Suzukake et al., 
2013; Sacino et al., 2013b; Sacino et al., 2014b). Different experimental outcomes in 
different studies may be explained by differing experimental conditions affecting the 
infectivity of α-synuclein fibrils, and important factors include: a) inoculum preparation, 
b) amount of inoculum, and c) injection site (Uchihara and Giasson, 2016). Some 
practical aspects of the mentioned factors are discussed in the following paragraphs. 
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a) Inoculum preparation: Buffer composition, shaking and sonication settings might 
affect the assembly of monomeric α-synuclein into fibrils (see 2.2.2 and 2.2.3). The 
conditions for fibril assembly often differ between studies (Luk et al., 2012a; Masuda-
Suzukake et al., 2013; Sacino et al., 2014b). In comparison to the protocol of Masuda-
Suzukake et al. (2013), the buffer used in the present study contained additional NaCl 
that could have resulted in the formation of fibrils with different properties. A buffer 
composition with reduced salt concentrations has been shown to cause different structural 
α-synuclein conformations, e.g. so-called ribbons, which show different seeding and 
propagation properties (Bousset et al., 2013). It has also to be considered that the 
assembly solution does not contain only fibrils but also oligomeric and prefibrillar α-
synuclein intermediates. These intermediates might be toxic and could also affect seeding 
properties (Karpinar et al., 2009; Winner et al., 2011). In contrast to one other protocol 
(Masuda-Suzukake et al., 2013), in the present study fibrils were not separated by 
centrifugation. Since different aggregation states can be distinguished in part by 
molecular weight, a separation of fibrils and intermediates by sedimentation velocity 
could improve characterization of aggregated α-synuclein species (Mok and Howlett, 
2006). Further influencing factors might be the duration of fibril assembly as well the 
sonication protocol that could generate divers α-synuclein species with different seeding 
efficiencies. For instance Masuda-Suzukake et al. (2013) only centrifuged and did not 
sonicate their fibrils during the entire assembly protocol. Whereas in the protocol of Luk 
et al. (2012) and the protocol used in the present study fibrils were only sonicated and not 
centrifuged after assembly.  
 
b) Amount of inoculum: The amount of α-synuclein seeds injected into mice might also 
influence their ability to form α-synuclein deposits and to cause neurodegeneration. In 
the present study 5 µg of α-synuclein fibrils were used for intracerebral injections. This 
amount has been reported to be sufficient to induce widespread α-synuclein pathology 
(Luk et al., 2012a). Masuda-Suzukake and colleagues injected 10 µg of fibrils, twice the 
amount that was injected by Luk et al. or in this study, which induced widespread α-
synuclein pathology but only after long incubation times (Masuda-Suzukake et al., 2013). 
Dose-dependency has been shown in a report by Sacino et al. (2013b) injecting 2 µg vs. 
25 µg into neonatal mice. In contrast to the low concentration that was not able to induce 
any signs of pathology, rare inclusions were found after injecting 25 µg of fibrils. 
Similarly, a dose-dependent induction of pathology has been reported in mice that 
received injections with viral vectors overexpressing α-synuclein (Oliveras-Salva et al., 
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2013; Sacino et al., 2013a). A correlation between the amount of α-synuclein inoculated 
and its pathogenicity has also been confirmed in primary neurons where the extent of 
induced pathology depends on the amount of α-synuclein inoculated (Volpicelli-Daley et 
al., 2014). 
 
c) Injection site: α-synuclein seeds injected into different brain regions might result in a 
different distribution and severity of α-synuclein pathology. The injection of α-synuclein 
fibrils e.g into the substantia nigra has been shown to be less virulent than the injection 
into the striatum (Luk et al., 2012a; Masuda-Suzukake et al., 2013).  
 
All the above-mentioned factors might synergistically influence each other and a detailed 
analysis is necessary to better understand how pathogenicity and disease progression is 
influenced. 
 
In general, the immunohistochemical or biochemical techniques utilized to assess α-
synuclein pathology could also affect the outcome of the results. In the present study, 
phosphorylated α-synuclein may have been detectable only at 400 dpi and not earlier by 
immunohistochemical techniques due to its low abundance. The detection of 
phosphorylated α-synuclein might be optimized by the pretreatment of tissue sections 
with formic acid or proteinase K to enhance the signal for α-synuclein deposits and reduce 
the signal for endogenous non-aggregated α-synuclein (Beach et al., 2008).  Pathology 
restricted to the cortex might explain why phosphorylated α-synuclein was not detected 
after immunoblotting of sarcosyl-insoluble fractions extracted from whole-brain 
homogenate. Due to a higher protein concentration extracted from the entire tissue, 
immunoblotting is generally considered as a more sensitive method than 
immunohistochemistry. In this respect, extracting from specifically dissected anatomical 
regions, such as the cortex, might enable detection of phosphorylated α-synuclein 
oligomers by immunoblotting.  
 
Since brain surgery is always accompanied by local inflammation, resulting changes in 
brain homeostasis might as well influence prion-like propagation efficiency. It has been 
clearly shown that persistent neuroinflammation caused by LPS promotes the 
development of neuropathology and neurodegeneration in a mouse model overexpressing 
α-synuclein (Gao et al., 2011).  However, according to the present data, the short, local 
inflammation caused by surgery is not accompanied by obvious long-term effects that 
possibly change disease progression (3.1.4). Despite the local inflammatory response, 
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induction of persistent neuroinflammation was not detectable as also observed in another 
study addressing the intracerebral injection of α-synuclein fibrils (Masuda-Suzukake et 
al., 2013). It is likely that the low abundance of α-synuclein inclusions restricted to the 
cortex was insufficient to activate astrocytes or microglia. Nevertheless, previous in vitro 
experiments have shown that misfolded α-synuclein activates microglia and can be 
directly transferred from primary neurons to astrocytes inducing an inflammatory 
response (Lee et al., 2010; Zhang et al., 2005). The induction of an inflammatory response 
might not only result from the accumulation of misfolded α-synuclein itself. It has been 
discussed that other circumstances like neuronal death and release of aggregated protein 
into the extracellular space might promote neuroinflammation (Glass et al., 2010). 
Moreover, α-synuclein aggregates that are posttranslationally modified by nitration have 
been shown to efficiently activate microglia and induce a neurotoxic response (Reynolds 
et al., 2008). In this respect, posttranslational modification like nitration might influence 
the capability of aggregated α-synuclein to activate immune cells. 
 
4.1.2 Intraglossal injection of α-synuclein prionoids did not induce 
neuropathology 
In contrast to prions that propagate within only two weeks from the tongue to the 
hypoglossal nucleus in the brainstem (Bartz et al., 2003), in the present work, injection 
of human α-synuclein fibrils into the tongue of Tg(Gfap-luc+/-) mice did not induce any 
neuropathology. Even within the tongue muscle, α-synuclein fibrils did not cause any 
protein deposition for up to 400 dpi (3.1.2). It may be supposed that prion-like 
propagation of pathogenic α-synuclein depends on the conversion of endogenous α-
synuclein. The assumption that the endogenous protein concentration is relevant for 
aggregate formation and seeding is supported by experiments in primary neurons. 
Exogenous addition of α-synuclein fibrils to primary neurons lead to an enhanced 
formation of aggregates when the concentration of endogenous α-synuclein was increased 
as in mature neurons (Volpicelli-Daley et al., 2011). The availability of neurons in the 
tongue muscle is limited to a few cranial nerves and therefore, it is likely, that the 
muscular tissue of the tongue might not express enough native α-synuclein to support its 
efficient conversion.  
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4.2 Mice overexpressing human α-synuclein are susceptible to 
peripherally injected α-synuclein fibrils 
4.2.1 Intraglossal injection of α-synuclein prionoids induced α-
synuclein pathology 
The present work shows that in comparison to the Tg(Gfap-luc+/-) mice, bigenic 
Tg(M83+/-:Gfap-luc+/-) mice overexpressing the A53T mutant of the human α-synuclein 
were more susceptible to exogenous challenge with α-synuclein fibrils via the tongue. It 
has been previously reported that homozygous Tg(M83+/+) mice develop a lethal 
movement disorder caused by widespread CNS accumulation of pathological α-synuclein 
(Giasson et al., 2002). For the present study, only heterozygous Tg(M83+/-) mice were 
used. These mice did not spontaneously accumulate pathogenic α-synuclein and remained 
free of neurologic disease for over 21 months as also reported by others (Watts et al., 
2013). However, the heterozygous overexpression of human α-synuclein was sufficient 
to induce distinct neuropathology in the CNS of one of five animals intraglossally injected 
with α-synuclein prionoids at 285 dpi (3.2.1 and 3.2.2). These results differ from a 
previous study, which reports no neuroinvasion in bigenic Tg(M83+/-:Gfap-luc+/-) mice 
injected intraglossally with 5 μL of 1 % MSA brain homogenate and sacrificed at 220 dpi 
(Prusiner et al., 2015).  
 
The intraglossal injection experiments into monogenic Tg(Gfap-luc+/-) and bigenic 
Tg(M83+/-:Gfap-luc+/-) mice cannot be directly compared. Tg(M83+/-:Gfap-luc+/-) mice 
were injected with 10 μg of α-synuclein fibrils, whereas Tg(Gfap-luc+/-) animals were 
injected with only 5 μg. For prions it has been shown that prion infectivity increases 
proportional to the concentration of prions intracerebrally inoculated (Tamgüney et al., 
2009a). As already discussed in 4.1.1 dose-dependency has also been shown to be 
relevant for injections with α-synuclein. Therefore, it might be interesting to verify if 
more inoculum may induce neuropathology in Tg(Gfap-luc+/-) mice or even increase the 
number of diseased Tg(M83+/-:Gfap-luc+/-) mice. Another explanation for the limited rate 
and severity of neuroinvasion after fibril challenge into the tongue muscle is that 
injections were not directly targeted to the bilateral hypoglossal nerve (cranial nerve XII). 
All intrinsic and extrinsic muscles of the tongue are innervated by the hypoglossal nerve, 
which originates from the hypoglossal nucleus (nucleus XII) in the brainstem (McClung 
and Goldberg, 2000). This nerve is the prevalent but not the only conduit innervating the 
tongue. Other cranial nerves such as the glossopharyngeal nerve also innervate the tongue 
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and might act as additional routes for α-synuclein seeds to neuroinvade the CNS. The 
hypoglossal nerve of LBD patients has been reported not to accumulate phosphorylated 
α-synuclein although other cranial nerves like the oculomotor, trigeminal, and the 
glossopharyngeal-vagus nerves, together with their roots display obvious α-synuclein 
pathology (Nakamura et al., 2016). Deposition of phosphorylated α-synuclein in both the 
brain and the spinal cord after intraglossal challenge supports the hypothesis of an initial 
retrograde axonal transport to the brainstem and from there to the spinal cord. 
Consequently, the findings of the present work, reaffirm that the intraglossal route is not 
only a pathway for bona fide prions (Bartz et al., 2003) but also for α-synuclein prionoids 
to neuroinvade the CNS. Although neuroinvasion of α-synuclein prionoids via the tongue 
is inefficient and takes seven weeks longer than that of prions, these findings indicate that 
α-synuclein prionoids have characteristics that are very similar to prions.  
 
4.2.2 Intraperitoneally injected α-synuclein fibrils induced severe 
neuropathology and neurologic illness 
The present work is the first to show that human α-synuclein prionoids can neuroinvade 
the CNS and induce neurologic disease in Tg(M83+/-:Gfap-luc+/-) mice after a single 
intraperitoneal injection with α-synuclein fibrils (3.2.1 and 3.2.3). Neuroinvasive 
properties were primarily described for bona fide prions (Kimberlin and Walker, 1986) 
and also found for β-amyloid and the tau protein (Clavaguera et al., 2014; Eisele et al., 
2010). Similar to our findings, a prion-like behavior was evident when brain extracts 
containing misfolded β-amyloid were injected into the peritoneum of APP23 mice. These 
animals, which express the human β-amyloid precursor protein with the Swedish 
mutation, developed β-amyloidosis in their brains after injection (Eisele et al., 2010). 
Similarly, intraperitoneal injection of brain stem extracts containing pathogenic tau 
aggregates into animals expressing the P301S mutant of tau, induces pathology in their 
brains (Clavaguera et al., 2014). Comparing the transmission routes and incubation times 
of α-synuclein prionoids to neuroinvade the CNS of Tg(M83+/-:Gfap-luc+/-) mice 
indicates that the efficiency to induce neuropathology along the intraperitoneal route is 
similar to the direct intracerebral route. Intraperitoneal injection causes disease only two 
weeks later (229 dpi) than after intracerebral injection with brain homogenate from 
diseased Tg(M83+/+) mice (216 dpi) (Watts et al., 2013). Unexpectedly, injection of 
human α-synuclein prionoids into the hindlimb muscles, the gastronemicus or the biceps 
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femoris, was reported to induce a much faster disease onset with obvious motor symptoms 
already at 129 dpi (Sacino et al., 2014a).  
 
There is evidence that the level of endogenous substrate protein expression is generally 
relevant for the seeded conversion of α-synuclein into its pathogenic form that is 
associated with disease as discussed in 4.1.2. In the Tg(APP23) mouse model for 
Alzheimer’s disease, which was intraperitoneally injected with β-amyloid, the level of 
cerebral β-amyloidosis was clearly dependent on the amount of endogenous amyloid 
precursor protein (APP) expressed (Eisele et al., 2014). For α-synuclein it is not yet clear, 
if overexpression of endogenous α-synuclein is a prerequisite to induce disease after 
intraperitoneal injection with α-synuclein fibrils. The results presented in 3.1.1 are in line 
with previous studies and show that endogenous overexpression is not a precondition for 
α-synuclein prionoids to cause CNS disease via the intracerebral route. Because 
intracerebrally injected α-synuclein fibrils are able to induce neuropathology in mice that 
are wild-type for α-synuclein (Luk et al., 2012a; Masuda-Suzukake et al., 2013; Sacino 
et al., 2013b). Only additional experiments in WT mice will help to clarify whether 
overexpression of α-synuclein is necessary for peripheral infection or not. Moreover, 
seeding efficiency might not only be determined by the level of endogenous protein 
expressed but also by molecular compatibility, which is often determined by sequence 
homology between native, endogenous α-synuclein and its fibrillary seed (Luk et al., 
2016). It has been shown in mice, that mouse α-synuclein fibrils show a higher propensity 
to seed aggregation than human α-synuclein fibrils. Substitution of a single amino acid in 
the mouse sequence was sufficient to alter its propensity to fibrillize in vitro and to seed 
misfolding of endogenous α-synuclein after injection into mice (Luk et al., 2016). As 
presented in 3.2.3.1 the aggregates found in the spinal cord of diseased animals were 
composed of endogenous mouse α-synuclein as well as transgenically expressed human 
α-synuclein. This clearly indicates that although the inoculated seed was human origin, 
both native mouse and transgenically expressed human α-synuclein are involved in the 
pathological process accelerating and amplifying the disease progression.  
 
The underlying mechanisms of how α-synuclein prionoids enter the CNS after 
intraperitoneal injection have not been thoroughly investigated yet. For prions it has been 
discussed that neuroinvasion might be possible by a) retrograde spreading of infectivity 
along peripheral nerves, or b) the hematogenous route (Siso et al., 2010). 
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Retrograde axonal transportation via peripheral nerves as a probable route for 
neuroinvasion of α-synuclein was confirmed by several inoculation studies. α-synuclein 
prionoids injected into the gastrocnemicus- or biceps femoris muscle of the hindlimb have 
shown to induce α-synuclein pathology in the CNS of Tg(M83+/-) or Tg(M83+/+) mice 
(Sacino et al., 2014a). The dissection of the sciatic nerve lead to a delayed or diminished 
induction of neuropathology indicating that the sciatic nerve is a probable route for 
neuroinvasion. However, since the induction of disease could not be completely abolished 
by nerve dissection, α-synuclein prionoids might also use additional routes, e.g. other 
peripheral nerves to enter the CNS. It has also been reported that human PD brain lysate 
or recombinant α-synuclein fibrils injected into the intestinal wall of rats were 
retrogradely transmitted via the vagus nerve to the brain stem causing neuropathology 
(Holmqvist et al., 2014). A similar long-distance propagation, was described after 
injection of human α-synuclein expressed from adeno-associated viruses into the vagus 
nerve in the rat neck (Ulusoy et al., 2013). The assumption that neuronal circuits are the 
prevalent transmission routes for disease-associated α-synuclein to neuroinvade the CNS 
was suggested after histopathological studies in patients with Lewy body disorders. The 
histological data revealed that α-synuclein pathology is not only restricted to the central 
or peripheral nervous system but also found in its innervated tissues and organs (Beach 
et al., 2010). The tissues along the digestive system, from the submandibular gland to the 
rectum, have been observed to be the most affected tissues and probably play an important 
role for the long-distance transmission of proteinaceous agents (Beach et al., 2010; 
Cersosimo and Benarroch, 2012; Hilton et al., 2014). 
 
The finding that red blood cells bear high concentrations of α-synuclein strengthens the 
possibility that blood could act as a reservoir for the replication, seeding, and 
dissemination of α-synuclein prionoids in the body (Barbour et al., 2008). Studies in rats 
have also suggested that misfolded α-synuclein species can cross the blood-brain barrier 
(BBB) after intravenous injection (Peelaerts et al., 2015). The induction of 
neuroinflammation as response to LPS has been shown to increase the permeability of 
the BBB (Banks and Erickson, 2010). Notably, in contrast to wild-type mice, Tg(SNCA-
/-) mice that are deficient for α-synuclein did not change their BBB permeability (Jangula 
and Murphy, 2013). These findings indicate that the presence of native α-synuclein is 
sufficient to enhance the permeability of the BBB and consequently to make the brain 
accessible for pathogens. For prions it has been reported that they can replicate outside of 
nervous tissue in follicular dendritic cells and secondary lymphoid tissues (Bruce et al., 
Discussion 
76 
2001; McCulloch et al., 2011). Whether α-synuclein prionoids can replicate in non-
nervous tissue and organs like such as the lymphatic system has not been investigated yet. 
Transmission of synucleinopathies by blood transfusion or organ transplantation has not 
been reported. In this respect it has to be considered that incubation times for the 
iatrogenic transmission of synucleinopathies are not known and could span several 
decades as has been observed for human prion diseases like kuru, which can take up to 
60 years (Collinge et al., 2006). Beside the iatrogenic transmission of prion diseases there 
is evidence that also amyloid-β associated with Alzheimer’s disease may have been 
transmitted via treatment with contaminated growth hormone or by dural grafting 
(Frontzek et al., 2016; Jaunmuktane et al., 2015a; Rudge et al., 2015).  
 
The results presented in 3.2.3.1 show that despite the wide distribution of α-synuclein 
pathology in the brains of Tg(M83+/-:Gfap-luc+/-) mice intraperitoneally injected with α-
synuclein fibrils certain anatomical regions were devoid of neuropathology. Detailed 
analysis of the brains revealed that neurons of the olfactory bulb, hippocampus, and 
cerebellum, including Purkinje and granule cells did not show any signs of α-synuclein 
deposition. Similar findings regarding this lack of pathology in these brain regions have 
been previously described but cannot be fully attributed to the prion promoter, which 
controls α-synuclein expression in M83 mice (Giasson et al., 2002). Indeed, the prion 
promoter is well known to drive expression in the hippocampus and Purkinje cells of the 
cerebellum (Tremblay et al., 2007). Since the complete lack of pathology is restricted to 
anatomical regions that contain granule cell populations (Franklin and Paxinos, 2008) it 
may be assumed that these neurons in the white matter do not support replication of 
misfolded α-synuclein. Also, in the spinal cord of diseased animals, α-synuclein 
pathology was restricted to the grey matter and not found within the white matter 
(3.2.3.1). These observations support the idea that long unmyelinated axons, as they are 
abundantly found in the grey matter, are more accessible and vulnerable than neurons 
surrounded by myelin sheets (Braak and Del Tredici, 2004). In particular, the cholinergic 
neurons of the ventral horn and the dopaminergic neurons of the substantia nigra 
accumulated deposits of misfolded α-synuclein (3.2.3.1 and 3.2.3.3). Both cell types are 
involved in controlling locomotor activity and their impairment possibly caused motor 
dysfunction in these mice. 
 
Moreover, the present results show that mice intraperitoneally injected with α-synuclein 
fibrils develop beside α-synuclein pathology, neuroinflammation in form of microgliosis 
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and reactive astrogliosis. Reactive astrocytes were detectable by BLI a few weeks before 
animals became terminally sick, similar to findings previously reported after intracerebral 
injection of MSA brain homogenate into Tg(M83+/-:Gfap-luc+/-) mice (Watts et al., 2013). 
The variability in BL intensities detected over time might be caused by dynamic 
regulation of GFAP expression, which is regulated by various signaling molecules 
(Sofroniew, 2009). Such mediator molecules are released by several cell types including 
microglia, oligodendrocytes, or leukocytes and gradually trigger the activity state of 
astrocytes. A rapid GFAP upregulation might also be explained by ependymal stem cells 
that are prompt to migrate to the CNS lesion and differentiate into astrocytes to stem the 
acute injury (Johansson et al., 1999). Despite such variability in measuring astrocytic 
gliosis, BLI can be used as surrogate marker to detect neuronal lesions some weeks before 
motor symptoms appear. 
 
4.3 Aerosols of pathogenic α-synuclein did not transmit disease  
In PD, neurons of the olfactory bulb or the enteric nervous system have been described 
as initiation points from where the disease progression could start (Braak et al., 2003a; 
Braak et al., 2004). The data presented in 3.3.1 show that aerosols made from MSA brain 
homogenate did not enter the olfactory epithelium and did not induce neuropathology or 
disease within 600 d in Tg(M83+/-:Gfap-luc+/-) mice. Similarly, direct instillation of 
recombinant α-synuclein fibrils or brain extracts containing pathogenic α-synuclein 
species from a LBD patient did not induce neuropathology in WT mice in 640 days when 
treated with weekly doses over one month (Masuda-Suzukake et al., 2013). In contrast, 
other agents like lipopolysaccharides LPS or MPTP (see intoxication mouse models 
1.5.1) have been shown to easily enter the brain by passing the nasal mucosa and induce 
PD-like pathology when directly instilled into the nostrils of rodents (He et al., 2013; 
Rojo et al., 2006). In addition, the nasal route via the olfactory epithelium was described 
as a very efficient route through which aerosolized CWD prions could enter the brain and 
induce disease in Tg(cerPrP) mice that express cervid PrPC (Denkers et al., 2010). 
Interestingly, aerosol mediated prion transmission has been shown to be more efficient 
than the direct instillation of infectious material into the nose. With regard to the present 
study, it cannot be completely excluded that pathogenic α-synuclein entered the olfactory 
epithelium, but remained under the threshold for immunohistochemical detection. 
Therefore it is recommendable to analyze whether the brain homogenates of mice 
exposed to aerosols might possibly seed aggregation in vitro and in vivo. In particular, 
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passage of the potentially pathogenic brain homogenates into mice would finally answer 
the question whether α-synuclein aerosols are able to mediate disease.  
 
However, one crucial factor that may influence particle absorption by the nasal mucosa 
is the size of the aerosolized particles. Since the nebulizer used for the present work 
(2.3.4) produced particles with a median diameter of 2.2 μm, it can be assumed that 
impaction is the major mechanism for their deposition in the nasal tracts (Vidgren and 
Kublik, 1998). For rodents it has been shown that aluminosilicate particles with a 
diameter larger than 3 μm are preferentially deposited in the nasal-pharyngeal region. For 
a particle size smaller than 3 μm, the deposition in the lung and bronchial airways 
increases (Raabe et al., 1988). This might explain why a supposedly sufficient amount of 
pathogenic α-synuclein to induce pathology may not have entered the nasal tracts and its 
epithelium. Beside the particle size, the short exposure time might also play a role in 
limiting the uptake of α-synuclein aerosols via receptor nerve endings. Therefore the 
influence of aerosol particle size and exposure times on the uptake of the pathogenic α-
synuclein via receptor nerve endings needs to be further investigated. In this respect, it 
should be considered that particles that enter the nasal tracts may also be transported by 
swallowed saliva to the gastrointestinal tract. According to the “dual hit hypothesis” this 
pathway is another potential route for α-synuclein to neuroinvade the CNS (Hawkes et 
al., 2007, 2009). 
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4.4 Conclusions 
The findings described here clearly show that similar to prions α-synuclein prionoids 
cause CNS neuropathology and disease after direct injection into the CNS and by 
neuroinvasion via several peripheral routes after peripheral injection. 
The findings in wild-type mice and mice overexpressing α-synuclein clearly show a direct 
correlation between the severity of α-synuclein pathology and the resulting disease 
phenotype. Intracerebral challenge of α-synuclein wild-type mice could recapitulate mild 
neuropathology as similarly observed in sporadic PD but not pathophysiological features 
like behavioral deficits and neuroinflammation. Induction of neuropathology via the 
intraglossal route in mice overexpressing α-synuclein shows that following oral ingestion 
pathogenic α-synuclein could be transmitted to the CNS via the cranial nerves. In 
particular, this pathway may have relevance when a superficial wound in the tongue 
facilitates the uptake of pathogenic α-synuclein or the entrance for other toxic agents. 
Moreover, the presented data provide the first evidence that the peritoneum is a potential 
entry site for α-synuclein prionoids to neuroinvade the CNS and cause neuropathology. 
Intraperitoneal injection of α-synuclein fibrils into mice overexpressing human α-
synuclein resembles important characteristics of human synucleinopathies recapitulating 
a distinct correlation between pathological, inflammatory, and physical hallmarks. In this 
respect, BLI is a suitable indicator for neuroinflammation preceding the appearance of 
motor symptoms. Moreover, intraperitoneal injection presents a suitable model to study 
peripheral routes through which α-synuclein possibly enters the CNS. The peritoneum 
and in particular the gastrointestinal system is of great interest since the progression of 
PD may start here. Although pathogenic α-synuclein aerosols did not pass the olfactory 
epithelium of mice and induce neuropathology, it remains recommendable to study this 
route more extensively since the olfactory cells are among the first cell populations 
affected in PD. In this respect, also the role of environmental factors like air pollution and 
pesticides entering the nose during daily life, should be included in further research. 
Despite many parallels with prions, it has to be further elucidated whether α-synuclein 
prionoids can overcome species barriers and are transmissible between organisms to 
induce disease. 
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5 Appendix  
5.5 Alignment of the amino acid sequences of mouse and 
human α-synuclein 
 
 
 
Fig. 5.1 Amino acid sequence of mouse and human α-synuclein. Both sequences differ in seven amino 
acids (red). The prevalent phosphorylation site of α-synuclein is at serine 129 (purple). Binding sites of the 
specific mouse and human antibodies are indicated: antibody D37A6, mouse specific (blue) and antibody 
Syn211, human specific (green). 
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5.6 Experimental overview 
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6 Abbreviations  
AD  Alzheimer`s disease 
AIF 1  allograft inflammatory factor 1 
ALP  autophagy-lysosomal pathway  
APP  amyloid precursor protein 
BBB  blood-brain barrier 
BL  bioluminescence 
BLI  bioluminescence imaging 
bp  base pair 
BSE  bovine spongiform encephalopathy 
ChAT  cholinergic acetyltransferase 
CJD  Creutzfeldt-Jakob disease 
CNS  central nervous system 
CuSO4  copper sulfate 
CWD  chronic wasting disease 
DA  dopamine 
DAB  3-3’-diaminobenzidine 
DNA  deoxyribonucleic acid 
d  day 
dpi  days post inoculation 
E. coli  Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
EGTA  ethylene glycol-bis (β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
EtOH  ethanol 
GCI  glial cytoplasmic inclusions 
GFAP  glial fibrillary acidic protein 
HCL  hydrochloric acid 
Hbb  human β-globin intron 2 
HPLC  high performance liquid chromatography 
HRP  horseradish peroxidase 
ic/ IC  intracerebral 
ID  identification number 
IF   immunofluorescence 
Abbreviations 
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ig /IG  intraglossal 
IHC  immunohistochemistry 
IL-1β  interleukin 1β 
IL-6  interleukin 6 
ip /IP  intraperitoneal 
IPTG  isopropyl β-D-1-thiogalactopyranoside 
kDa  kilodalton 
LB  Lewy body 
LB  lysogeny broth 
LBD  Lewy body dementia 
LBVAD Lewy body variant of Alzheimer`s disease  
LN  Lewy neurite 
LPS  lipopolysaccharide 
Luc2  luciferase gene 2 
kb  kilobase 
rpm   rotation per minute 
MAPT  microtubule associated protein tau 
MgSO4 magnesium sulfate 
MSA  multiple system atrophy 
MPP+        1-methyl-4-phenyl-pyridium 
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
NaCl  sodium chloride 
(NH4)2SO4 ammonium sulfate 
No./ no. number 
nTg  non transgenic 
OD  optical density 
TBS  Tris-buffered saline 
TH  tyrosine hydroxylase 
p  phospho 
PCR  polymerase chain reaction  
PBS   phosphate-buffered saline   
PD  Parkinson`s disease 
PDGF β platelet-derived growth factor-β 
PFA  paraformaldehyde 
Abbreviations 
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PFF  preformed fibrils 
PolyQ  polyglutamine 
PrP  prion protein 
PVDF  polyvinylidene difluoride 
RML  RML (Rocky mountain laboratory) prion 
ROI  region of interest 
RT  room temperature 
SD  standard deviation 
Ser129  serine 129 
SEM  standard error of the mean 
SNc  substantia nigra pars compacta  
Snca  gene encoding mouse α-synuclein 
SOD1  superoxide dismutase 1 
SYN  α-synuclein 
TEM  transmission electron microscopy 
TH  tyrosine hydroxylase 
TME  transmissible mink encephalopathy 
TNF-α  tumor necrosis factor α 
UPS  ubiquitin-proteasomal system 
vCJD  variant Creutzfeldt-Jakob disease 
w/v  weight per volume 
WB   western blot 
6-OHDA 6-hydroxdopamine 
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7 Contributions 
Expression and purification of recombinant human α-synuclein protein was performed by 
Dr. Julius Tachu Babila at the German Center of Neurodegenerative Diseases, Bonn. The 
mouse α-synuclein fibrils in Fig. 3.1 were analyzed by electron microscopy by Karen 
Tolksdorf at the Department of Neurology of the University of Bonn. The human α-
synuclein fibrils in Fig. 3.9 were analyzed by electron microscopy by Dr. Maria C. Garza 
and Dr. Holger Wille at the University of Alberta in Edmonton, Alberta. 
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